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 ABSTRACT 
 
Staphylococcus pseudintermedius is the most common microorganism isolated 
from canine pyoderma and opportunistic infections. Prevalence of methicillin-resistant S. 
pseudintermedius (MRSP) has increased and multi-drug resistance has become common. 
A total of 734 S. pseudintermedius isolates collected from dogs presented to the 
Veterinary Medical Teaching Hospital from 2007 to 2012 were studied. Isolates were 
analyzed for antimicrobial resistance and virulence gene carriage.   
With the emergence of methicillin resistance, veterinarians have begun to use 
antimicrobials such as amikacin, to treat life-threatening MRSP infections. The most 
widespread mechanism of amikacin resistance is drug inactivation by aminoglycoside 
modifying enzymes (AMEs). The most prevalent gene detected here was aph(3′)- IIIa 
found in 75% (24/32) of isolates followed by aac(6′)/aph(2′′) and ant(4′)-Ia in 12% 
(4/32) and 3% (1/32), respectively. There was a significant association between 
amikacin and methicillin resistance. Since AMEs can be transferred from one bacteria to 
another, amikacin resistance may represent a new nosocomial and zoonotic threat. 
Clindamycin is an alternative to β-lactam antimicrobial therapy for canine 
pyoderma. Inducible and constitutive resistance to clindamycin can occur. 
Approximately forty erm genes encoding methylases involved in clindamycin resistance 
have been reported, with ermB most commonly found among S. pseudintermedius. We 
found eight of 608 isolates tested, positive for inducible clindamycin resistance by D-test 
and PCR detection of ermB.   
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 A vaccine against staphylococcal pyoderma would reduce the reliance on 
antimicrobial drugs. Staphylococcal cell-wall associated proteins (CWAPs) involved in 
colonization of the host are attractive potential vaccine targets. Eighteen CWAPs 
encoded by sps genes have been described in S. pseudintermedius; however, four vary in 
occurrence. Isolates were analyzed by polymerase chain reaction (PCR) for the presence 
of mecA, SCCmec type I-VI, and spsF, spsO, spsP, and spsQ. There was a significant 
association between methicillin resistance and carriage of spsP and spsQ. spsP and spsQ 
may be viable vaccine targets.  
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 NOMENCLATURE 
 
AACs Aminoglycoside acetyltransferases 
APHs Aminoglycoside phosphotransferases 
ANTs Aminoglycoside nucleotidyltransferases 
AMEs Aminoglycoside modifying enzymes 
AR Amikacin-resistant only 
ARMR Amikacin and methicillin-resistant 
ccr Cassette chromosome recombinases 
CLSI Clinical and Laboratory Standards Institute 
CWAPs Cell wall-associated proteins 
D-Test Double-disk diffusion test 
MIC Minimum inhibitory concentration 
MLS Macrolide, lincosamides, streptogramin B 
MRSA Methicillin-resistant Staphylococcus aureus 
MRSP Methicillin-resistant Staphylococcus pseudintermedius 
MSSP Methicillin-susceptible Staphylococcus pseudintermedius 
MR Methicillin-resistant only 
OR Odds ratio 
PBP2a Penicillin binding protein 2a 
PCR Polymerase chain reaction 
S. Staphylococcus 
SD Standard deviation 
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 SCCmec Staphylococcal cassette chromosome mec 
ST Sequence type 
VMTH Veterinary medical teaching hospital 
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 CHAPTER I  
INTRODUCTION 
 
Background 
Staphylococcus pseudintermedius is the most frequent causative agent of canine 
pyoderma and is also associated with opportunistic infections in dogs (i.e., otitis externa, 
urinary tract infections, and surgical and non-surgical wound infections) (1,2). Many 
dogs harbor S. pseudintermedius in their nares and elsewhere on their skin without 
having clinical evidence of disease and may serve as a potential source of infection for 
other animals and humans as well (1,3,4). Most S. pseudintermedius are susceptible to β-
lactam antibiotics such as amoxicillin but some are resistant to these drugs either due to 
the production of a β-lactamase, encoded by bla, or acquisition of an altered penicillin 
binding protein that has a low affinity for all β-lactam antibiotics, encoded by mecA. As 
a result of acquisition of these genes, β-lactam antibiotics are rendered ineffective and 
the bacteria become resistant (1,5,6). Both bla and mecA can be transmitted between 
Staphylococcus spp. so dogs colonized with S. pseudintermedius carrying these genes 
may serve as reservoirs of antibiotic resistance (7,8). 
Empirical treatment of staphylococcal infections such as pyoderma and 
secondary post-operative infection typically involves β-lactam antibiotics such as 
penicillins and cephalosporins (9). In recent years isolation of methicillin-resistant S. 
pseudintermedius (MRSP) from canine skin has become a common occurrence raising a 
number of questions about the diagnosis, treatment, and prevention of these infections. 
As prevalence rates of MRSP increase, veterinarians have used other classes of 
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 antimicrobial drugs to treat infections; however, resistance to these drugs has also 
increased. Studies from Europe have demonstrated that 90% of MRSP isolates were 
resistant to clindamycin, erythromycin, and trimethoprim, 70% were resistant to both 
chloramphenicol and gentamicin, and 57% were resistant to just chloramphenicol (2,10). 
Resistance has begun to emerge in the United States: over the past five years, resistance 
to chloramphenicol has become common leading to the reliance on drugs such as 
amikacin to treat MRSP infection (11,12).  
Amikacin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis 
by binding to the 30S ribosomal subunit (13). The most widespread mechanism of 
aminoglycoside resistance is drug inactivation by cellular aminoglycoside modifying 
enzymes (AMEs) encoded on the chromosome, a plasmid, or carried on a transposable 
element (14-17). They can be divided into three classes: aminoglycoside 
acetyltransferases (AACs), aminoglycoside (phosphotransferases (APHs), and 
aminoglycoside nucleotidyltransferases (ANTs) (18). In S. aureus, the aac(6′)/aph(2′′) 
gene is the most frequently encountered aminoglycoside resistance gene followed by 
ant(4′)-Ia and aph(3′)- IIIa (18,19). Each gene encodes the following enzyme 
respectively: AAC(6’)/APH(2”), ANT(4’)-I, and APH(3’)-III (18).  
Clindamycin is a lincosamide that reversibly binds to the bacterial 50S ribosomal 
subunit thereby inhibiting protein synthesis (20). In some cases, staphylococci may 
appear to be susceptible to clindamycin when tested in vitro, but the infected patient may 
fail to respond to therapy despite being treated with what seems to be an appropriate 
drug concentration for an appropriate duration. Lincosamides bind to the same or closely 
related binding sites in the bacterial ribosome as macrolides such as erythromycin. 
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 Resistance to macrolides, lincosamides, and streptogramin B antibiotics (MLSB 
phenotype) can occur through acquisition of a methylase enzyme that removes a methyl 
group from an adenine residue in the 23S ribosomal RNA component of the 50S subunit 
of the ribosome (21-23). Removal of this methyl group alters the site to which the 
antimicrobial drug binds altering its efficacy. Approximately forty erm genes that 
encode methylases have been reported in different bacterial genera, with ermA, ermB, 
and ermC the most commonly found among staphylococci (24). In S. aureus, ermA and 
ermC confer erythromycin resistance in 94-98% of isolates (25). In S. pseudintermedius, 
ermB is primarily responsible for MLSB resistance, but its expression can be constitutive 
or inducible (11). Routine antimicrobial susceptibility testing can detect constitutive 
MLSB resistance but fails to detect inducible resistance (26). Inducible clindamycin 
resistance can result in treatment failure and should be suspected in isolates that are 
erythromycin-resistant but clindamycin-susceptible on in vitro antimicrobial 
susceptibility testing. 
Several studies have measured the prevalence of MRSP. In Canada, MSRP was 
detected in only 2.1% of dog patients (5). Morris et al. in Pennsylvania showed 6.2% 
carriage prevalence in dogs in 2010 (1). However in Japan, MRSP has been detected in 
even greater numbers among inpatient (46.2%) and outpatient (19.4%) dogs in a 
veterinary teaching hospital (5). Risk factors for carriage include recent antibiotic 
treatment (within the last six months), recent corticosteroid treatment, prior 
hospitalization, and veterinary contact within the last 4 weeks. Dogs treated with 
antimicrobial drugs were more likely to carry MRSP (12.6%) as compared to 2.3% of 
untreated dogs (10).  
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In order to determine the relatedness of S. pseudintermedius isolates, a 
combination of strain typing methods are used including pulse-field gel electrophoresis 
(PFGE), multilocus sequence typing (MLST), spa typing, mecA PCR, and SCCmec 
typing (27). PFGE is laborious and is commonly used although no standardized protocol 
exists (2). SCCmec typing is a standard method and is used throughout the literature 
either alone or in combination with other testing methods (2,5,8). 
SCCmec identified as the Staphylococcal Cassette Chromosome mec is a mobile 
genetic element that is characterized by a combination of mec and ccr gene complexes 
(2,5). SCCmec typing is a molecular tool to examine the epidemiology of methicillin-
resistant staphylococci (5). SCCmec types vary in different parts of the world. There is 
still little known about the population genetics of MRSP but the general consensus is 
that in Europe SCCmec II-III on strain ST71 dominates while in North America SCCmec 
V on strain ST68 is much more commonly isolated (5,8,28). Within North America, 
most of the research on mec typing has been done in Canada and the northeastern United 
States and Tennessee. To the best of our knowledge, no data has been published 
evaluating regional clonality of MRSP in Texas. 
Finally, the colonization or carriage of S. pseudintermedius on the skin requires 
adherence to epithelial surfaces which typically requires tight attachment between host 
and bacterial proteins. The bacterial proteins involved are usually proteins found on the 
outer surfaces of the bacteria such as the outer membrane or cell wall. A recent study in 
S. pseudintermedius identified 18 cell wall associated proteins (CWAPs) that are 
involved in attachment to host proteins (29). This study demonstrated that there is 
variation in carriage of four of these 18 proteins; specifically SpsF, SpsO, SpsP, and 
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 SpsQ are not found in all isolates of S. pseudintermedius (29). Studies evaluating the 
differences in the carriage of these proteins between isolates collected from dogs with 
pyoderma or other types of staphylococcal infection or between isolates that are MRSP 
and methicillin-susceptible S. pseudintermedius (MSSP) have not been published. 
Determining which virulence factors are required for colonization and infection may 
allow the development of novel strategies to reduce skin infection, including 
development of targeted therapeutics, and the rational design of staphylococcal vaccines. 
In conclusion, these data suggest that mechanisms of antibiotic resistance in S. 
pseudintermedius are complex and widespread. New avenues of treatment will need to 
be explored in order to combat this ever-growing threat to the canine patient population. 
We hypothesized that the four CWAPs that show variation in S. pseudintermedius would 
be associated with strains associated with skin infection or strains that were resistant to 
antibiotics (i.e., methicillin-resistant). We further anticipated that these strains would be 
more likely to contain the SCCmec type V than other SCCmec types since the SCCmec 
type V has been shown to be the common type in North America. We also hypothesized 
that S. pseudintermedius strains would carry one or more of the three amikacin 
resistance genes previously discovered in S. aureus and that gene carriage would be 
associated with strains that are more resistant (i.e., methicillin-resistant). Finally, we 
anticipated that isolates carrying inducible clindamycin resistance would be present 
within our collection of isolates and resistance would be due to the carriage of the 
resistance gene ermB.  
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 Purpose and objectives 
The purpose of this study was to determine the epidemiology and microbiology of 
Staphylococcus pseudintermedius isolates among canine patients admitted to the Texas 
A&M Veterinary Medical Teaching Hospital. The objectives of this research included: 
• To determine the carriage of specific cell-wall associated proteins in S. 
pseudintermedius isolates collected from dogs with skin infection, dogs with other 
types of infections, and dogs without clinical infection presented to the VMTH. 
• To determine whether carriage of these CWA proteins differed between S. 
pseudintermedius isolates that were MRSP or MSSP. 
• To determine the incidence of amikacin resistance in S. pseudintermedius isolated 
from dogs presented to the VMTH. 
• To identify the amikacin resistance genes carried by these strains and to describe 
their antimicrobial susceptibility. 
• To determine whether there was any difference in the carriage of amikacin resistance 
genes between isolates that were MRSP and MSSP. 
• To determine whether amikacin resistance in S. pseudintermedius was related to a 
prior history of drug exposure with or without the presence of methicillin resistance. 
• To determine the incidence of inducible clindamycin resistance in S. 
pseudintermedius isolated from dogs presented to the VMTH. 
• To determine if ermB was carried by strains that exhibited a positive D-Test 
• To determine if there was a history of prior antibiotic exposure in strains that 
demonstrated a positive D-Test.  
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CHAPTER II 
LITERATURE REVIEW∗ 
Isolation of MRSP from canine skin has become a common occurrence. The increased 
prevalence of MRSP in dogs in recent years (30) has raised a number of questions about 
the diagnosis, treatment, and prevention of these infections. Concerns about transmission 
of methicillin-resistant staphylococci can impact interactions between humans and their 
pets and affect patient care in veterinary practices (30). Unfortunately, in some 
situations, owners have been advised to remove pets from their households or even 
euthanize them because of concerns regarding transmission of these organisms (31). For 
these reasons, it is important that veterinarians understand the difference between MRSA 
and MRSP and know how to interpret positive culture results for these organisms in 
samples collected from dogs. Understanding staphylococcal infections has become 
increasingly important and challenging in recent years. The purpose of this report is to 
describe recent discoveries and advancements in our understanding of staphylococcal 
infections, particularly MRSP infection, in dogs and to summarize the available 
information regarding potential zoonotic transmission of these agents. 
Staphylococci of importance in human and veterinary patients 
Staphylococci are gram-positive, facultative, anaerobic cocci and are indigenous flora of 
the skin and mucous membranes of healthy dogs (32). Staphylococci cause opportunistic 
∗ Reprinted with permission from “Understanding methicillin resistance in canine 
pyoderma” by Gold RM, Patterson AP, Lawhon SD, 2013. Journal of American 
Veterinary Medical Association, 243, 817-824, Copyright [2014] by American 
Veterinary Medical Association. 
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 infections characterized by exudative lesions with local tissue inflammation (32). Skin 
infections are the most common type of staphylococcal infection, although bacteremia 
and life-threatening systemic disease (i.e., toxic shock syndrome) can occur (33). 
Microscopic examination of lesion exudates reveals cocci in clusters, pairs, or short 
chains, and neutrophils (34).  
More than 50 species and subspecies of Staphylococcus have been described 
(35). Historically, the ability of staphylococci to clot plasma was considered predictive 
of virulence, and staphylococci with this capacity were described as coagulase positive 
(36). Previously, coagulase-positive staphylococci isolated from dogs were classified as 
either Staphylococcus aureus or Staphylococcus intermedius. In 2005, all 
Staphylococcus isolates from dogs previously identified as S. intermedius were 
reclassified as Staphylococcus pseudintermedius, a species in the S. intermedius–related 
group, on the basis of growth characteristics and biochemical features (37). First 
described in 1999 (38) and expanded in 2005, the S. intermedius–related group consists 
of closely related coagulase-positive staphylococci that differ in their host specificity 
(39,40). The group includes S. pseudintermedius, predominantly isolated from dogs, S. 
intermedius, isolated from pigeons, and Staphylococcus delphini, which has been found 
in a variety of animals including dolphins, mink, cattle, and horses (37,39,41).  
Subsequent to this reclassification, S. pseudintermedius has been considered the 
predominant cause of superficial pyoderma as well as a leading cause of otitis and of 
opportunistic infections at surgical sites in dogs (4,28,42-46). Two studies (47,48) 
demonstrated that Staphylococcus schleiferi subsp schleiferi, which is coagulase 
negative, is also frequently isolated from dogs with skin disease. Although S. aureus is a 
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 leading cause of infections in humans, it is less commonly isolated from dogs than is S. 
pseudintermedius (43,46,49). Infection with S. pseudintermedius typically results from a 
disruption affecting normal cutaneous homeostasis or from an underlying disease 
process (40). S. pseudintermedius can be readily cultured from samples collected from 
the nose, oral cavity, intestinal tract, urogenital tract, groin, and perineal regions of 
healthy dogs (49). In healthy dogs, reported frequencies for recovery of the organism 
were 8 of 69 (12%) (49), 54 of 150 (36%) (50), and 6 of 43 (14%) (51) from the nares, 
and 14 of 69 (20%) (49), 27 of 74 (36%) (50), and 14 of 43 (33%) (51) from the anal 
mucosa. Additionally, S. pseudintermedius is cultured more frequently from swabs of 
the rostral nares and anal mucosa of dogs that live in multidog households than from 
dogs that do not; this may reflect normal canine social behavior, such as sniffing the 
perianal region, which could facilitate transfer of staphylococci between animals (50).  
Methicillin resistance 
Antimicrobial resistance in staphylococci 
Historically, infections with staphylococci were associated with high morbidity and 
mortality rates in humans (32). With the discovery of penicillin, this changed. Penicillin 
and other β-lactam antimicrobials act by binding to and inhibiting the transpeptidase 
required for crosslinking of peptidoglycan in bacterial cell walls (52). With β-lactam 
drug treatment, the peptidoglycan layer weakens and the bacteria are killed by increased 
osmotic pressure and cell rupture (52). Some staphylococci produce a β-lactamase 
enzyme that destroys the β-lactam ring of penicillins and related antimicrobials, 
rendering them ineffective (32,52). Methicillin was developed as a β-lactamase–resistant 
antimicrobial. Within a year after the introduction of methicillin in 1960, the first MRSA 
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 strains were identified (53). Methicillin was quickly discarded as a therapeutic drug 
because of adverse effects; however, β-lactam–resistant staphylococci are still referred to 
as methicillin-resistant (54). Methicillin-resistant staphylococci are resistant to all β-
lactam antimicrobials including cephalosporins, penicillins, and amoxicillin-clavulanate 
combinations (55). Many MRSP isolates are resistant not only to β-lactam drugs but also 
to one or more macrolides, lincosamides, trimethoprim-sulfonamide combinations, or 
fluoroquinolones (48,55). Chloramphenicol, tetracyclines, aminoglycosides, and 
rifampin remain drugs to consider for treatment of MRSP infection, however, culture 
and susceptibility testing should always be performed to evaluate susceptibility to these 
drugs (55).  
Methicillin resistance genes 
Penicillin binding protein 2a is a transpeptidase that has a low affinity for all β-lactam 
antimicrobials (5,6,11,56-58). This protein is encoded by the mecA gene, and 
staphylococci that carry mecA are resistant to all β-lactam drugs (1,5,6,56). The 
evolutionary origin of mecA is unknown; however, the authors of 1 study (59) suggested 
that it may have originated within the genus of Staphylococcus from a mecA homologue 
identified in Staphylococcus sciuri, a coagulase-negative organism commonly isolated 
from animals.  
The mecA gene is carried on a transmissible mobile DNA element called 
SCCmec (11). The SCCmec can be transferred from one Staphylococcus isolate to 
another of the same or different species (8). Thus an isolate of S pseudintermedius that is 
susceptible to β-lactam drugs can become resistant to these agents through horizontal 
transfer of SCCmec from a resistant isolate, creating a new strain of MRSP (8). The 
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 SCCmec contains the mec gene complex which consists of mecA, the genes that control 
expression of the mecA gene, and unique site specific recombinases called cassette 
chromosome recombinases (11). Typing of SCCmec is performed through analysis of 
the cassette chromosome recombinase gene complex and the mec gene complex. The 
International Working Group on the Staphylococcal Cassette Chromosome elements has 
defined 11 SCCmec types in S. aureus to date (60). At least five of these SCCmec types 
(II–III, III, IV, V and VII-241) as well as two non-typeable cassettes have been 
identified in S pseudintermedius (11).  
Once established, MRSP strains carrying specific SCCmec types typically 
dominate in a geographical region (8). Accordingly, it becomes possible to use SCCmec 
typing in epidemiologic studies to monitor for clonal spread of antimicrobial resistance 
and to assess zoonotic disease patterns. In addition, MRSP strains can be further grouped 
via ST, which is determined through evaluation of alleles in 7 or more different loci to 
create an allelic profile for each isolate (11). There is still limited information available 
regarding the population genetics of MRSP, but in North America, strain ST68 with 
SCCmec V has been commonly isolated, whereas in Europe, strain ST71 with SCCmec 
II-III has dominated (5,8,11,28). There has been some debate about whether MRSP with 
SCCmec II-III or SCCmec III is the primary type found in Europe (11,27,57). The 
apparent differences among studies may be related to differences in the methodology 
used for typing (2,57).  
Identification of methicillin-resistant staphylococci 
Methicillin-resistant staphylococci are identified through detection of mecA via DNA-
based tests such as PCR assays, antibody-based agglutination tests to detect penicillin 
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binding protein 2a, or in vitro antimicrobial susceptibility testing (61-63). Antimicrobial 
susceptibility testing includes assessment of resistance to oxacillin by means of disk 
diffusion or MIC testing (62,64). Evaluation of cefoxitin resistance is also used as a test 
for methicillin resistance in S aureus and coagulase-negative staphylococci, but is less 
reliable for testing of S pseudintermedius (62,65). Consequently, it is important that 
oxacillin, not cefoxitin, be used for identification of MRSP through antimicrobial 
susceptibility testing (62,65). Studies (62,65) have shown that the 2004 Clinical 
Laboratory Standards Institute oxacillin disk diffusion and MIC breakpoints of ≤ 17 mm 
and ≥ 0.5 μg/mL, respectively, predict mecA-mediated methicillin resistance in S 
pseudintermedius better (i.e., fewer false susceptible results) than the current 2008 
criteria.   
Pyoderma in dogs 
Classification and diagnosis 
Pyoderma is the most common skin disease in dogs and is defined as a pyogenic 
infection of the skin. When lesions are present, they are typically found on the ventral 
aspects of the abdomen and trunk, groin, muzzle, interdigital regions, and axilla (1,66). 
Superficial pyoderma is characterized by erythema of the skin with follicular or 
nonfollicular papules and vesiculopustules that give rise to yellowish exudates or crusts 
(43,67). Superficial pyoderma may progress to a deeper form of disease that affects 
structures below the epithelium. With deep pyoderma, the predominant lesions often 
manifest as erythematous, exudative, alopecic nodules, draining tracts, and surrounding 
friable skin with surface ulcers (68). Importantly, superficial and deep pyodermas often 
develop secondary to an underlying disease process. These can include immune-
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 mediated diseases, endocrinopathies, ectoparasitism, cornification defects, adverse drug 
reactions, foreign bodies, and neoplasia (69,70). In these situations, it is important not 
only to treat the bacterial infection but also to properly diagnose and treat the inciting 
cause of secondary pyoderma (69). Management of the bacterial infection consists of 
topical or systemic treatments or combinations of these (12).  
Pyoderma caused by methicillin-resistant staphylococci is clinically 
indistinguishable from that caused by methicillin-susceptible strains (67). However, 
pyoderma in dogs with methicillin-resistant staphylococcus infection can manifest as 
visible lesions 2 to 3 weeks after the initiation of empirical treatment, with bacteria 
detected on repeated cytologic examination. When empirical treatment fails, culture and 
antimicrobial susceptibility testing of samples is essential for choosing an appropriate 
alternate antimicrobial (32,49). Although MRSP is not more virulent than methicillin-
susceptible S pseudintermedius, and the outcomes following appropriate treatment can 
be the same, proper antimicrobial selection is essential for success (67). Further, when 
an animal with a prior history of infection with methicillin-resistant staphylococci 
develops a subsequent infection or another pet in the same household develops an 
infection, a sample should always be collected for culture and susceptibility testing 
rather than initiating empirical treatment (12).  
Careful collection of material is essential when obtaining samples for culture 
from the skin. Aspiration of material from an intact pustule is preferred; however, in 
dogs with superficial pyoderma, pustules are frequently transient, leaving circular, often 
alopecic skin lesions with exfoliative borders (commonly referred to as epidermal 
collarettes) on the skin (71). Results of some studies (71,72) have indicated that 
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 epidermal collarettes are a characteristic of superficial pyoderma in dogs. In 1 study 
(71), bacteriologic culture of S. pseudintermedius from epidermal collarette swabs was 
successful for 18 of 22 dogs with superficial pyoderma, with 81.8% sensitivity and 
100% specificity. Biopsy of the skin can also be performed to obtain sufficient tissue 
samples for diagnostic testing, particularly in cases of deep pyoderma when bacteria 
have infiltrated the underlying dermis (73).  
Treatment 
First-time cases of canine pyoderma are typically treated empirically, on the basis of the 
clinician’s experience, without culture and susceptibility testing (74). Antiseptic 
shampoos that contain benzoyl peroxide, chlorhexidine, ethyl lactate, triclosan, or 
salicylic acid are commonly used for treatment of superficial pyoderma in dogs (75). 
Investigators in 1 study (67) found that use of topical treatments alone resulted in 
clinical resolution of staphylococcal pyoderma in 17 of 26 cases, with clinical 
improvement in 4 of the remaining cases. These treatments are often prescribed when 
large areas of the body are affected or when haired skin is involved (76). A full 
description of effective topical treatments for staphylococcal pyoderma can be found 
elsewhere (76). Topical products can be used alone or in conjunction with systemic 
antimicrobial administration (9). Although topical treatments offer some advantages 
over systemic treatment, such as higher local antimicrobial concentrations, these may not 
always be adequate to achieve clinical resolution of pyoderma (77).  
For empirical systemic treatment of pyoderma in dogs, amoxicillin-clavulanic 
acid or first-generation cephalosporins (i.e., cephalexin) are the drugs most commonly 
selected (9). Clindamycin has been recommended as an appropriate alternative choice on 
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 the basis of its favorable safety profile, clinical efficacy, and distribution into the skin 
(9,12). Cefovecin and cefpodoxime proxetil are third-generation cephalosporins that are 
convenient for use in dogs because they do not require frequent administration. 
However, these drugs are only recommended as first-line agents in situations where 
owner compliance is a concern, because they have the potential to select for both 
methicillin-resistant staphylococci and extended spectrum β-lactamase producing 
organisms (9). Although effective against many staphylococcal isolates, trimethoprim-
sulfonamide combinations should be avoided for long-term use because of potential 
adverse effects such as keratoconjunctivitis sicca, blood dyscrasias, and hypothyroidism 
(78). In dogs with recurrent infection, a sample should be collected from a lesion for 
culture and susceptibility testing to guide proper drug selection (12).  
Treatment for superficial pyoderma should be continued for 1 week past the 
resolution of clinical signs; this would typically require ≥ 3 weeks of treatment (9). 
Because of the increased depth and severity of lesions in dogs with deep pyoderma, a 
minimum treatment period of 4 weeks should be considered, with an endpoint of 2 
weeks past the resolution of clinical signs (9). It is important that the patient be 
reexamined and that cytologic evaluation of aspirates and impression smears be repeated 
during the course of treatment to assess the patient’s response. Otherwise, if infection is 
detected after the end of the treatment period, it becomes difficult to determine whether 
the patient has been reinfected or the original treatment protocol has failed because of an 
incorrect antimicrobial choice or premature discontinuation of an appropriate drug 
regimen. Overall prognosis is good if the underlying cause can be identified and 
corrected or well-controlled to prevent recurrent infection (69). As previously 
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 mentioned, conditions that predispose dogs to pyoderma can hinder successful 
management of the infection if not properly addressed (12).  
When infection with methicillin-resistant staphylococci has been identified, 
proper drug choice is essential. Topical treatments can be provided but should only be 
used as adjuncts to systemic antimicrobial treatment administered at the correct dosage 
on the basis of the dog’s current body weight and given for the prescribed period (12). A 
methicillin-resistant Staphylococcus infection should not be treated with β-lactams, 
cephalosporins, or amoxicillin-clavulanic acid as these are ineffective against the 
bacteria (11,32,55). Fluoroquinolones are often a poor choice for long-term treatment, 
because susceptible strains quickly develop resistance to this class of drugs 
(48,55,79,80). Development of resistance against trimethoprim-sulfonamide 
combinations and clindamycin has also been reported (55). In addition, it is important to 
note that inducible clindamycin resistance can occur, wherein an isolate appears 
susceptible in vitro, but resistance is induced during treatment of the patient, resulting in 
treatment failure (81). Specialized laboratory testing can detect inducible clindamycin 
resistance when an isolate is susceptible to clindamycin but resistant to erythromycin 
(81).  
Currently, aminoglycosides (i.e., gentamicin or amikacin), tetracyclines (i.e., 
doxycycline or minocycline), rifampin, and chloramphenicol are considered potentially 
therapeutic choices for treatment of methicillin-resistant staphylococci with multiple 
drug resistance if MIC testing confirms susceptibility to 1 or more of these agents (55). 
All drug choices require evaluation of patient factors that would contraindicate selection 
of a drug. In particular, well-known, serious adverse effects may occur with each of 
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 these drugs. Aminoglycosides can have nephrotoxic effects (12,55). Doxycycline has 
been reported to rarely cause renal or liver injury and esophageal lesions, especially in 
cats (55). The most common adverse effect of rifampin is hepatotoxicity, but 
gastrointestinal disturbances and orange-red discoloration to the urine, tears, and sclera 
have also been noted (12,55). In dogs, chloramphenicol can cause gastrointestinal upset 
and weight loss and uncommonly results in liver toxicosis, bone marrow suppression, 
weakness, and neurologic tremors (12). Additionally, this drug can have serious adverse 
effects such as aplastic anemia and bone marrow suppression in humans, and therefore 
requires special handling (12,55). Chloramphenicol can also have adverse interactions 
with several classes of drugs, because it interferes with the cytochrome P450 pathway 
and thus decreases clearance of other drugs metabolized by this pathway (55).  
Additional factors specific to treatment of methicillin-resistant staphylococcal 
infection should also be considered when choosing an appropriate antimicrobial agent. 
Rifampin should not be used alone because resistance develops rapidly under these 
circumstances (28,82,83). In a 2011 study (82) of dogs with MRSP infection, resistance 
to rifampin emerged rapidly, even when the drug was used in combination with other 
antimicrobials. Chloramphenicol has been an important agent for treatment of MRSP 
infection in dogs, because historically MRSP has been susceptible to this drug. However, 
in Europe, chloramphenicol resistance in MRSP has become widespread (11,12). This is 
of particular concern because MRSP has only been reported since 2007 in Europe, and 
the finding suggests that chloramphenicol resistance has developed rapidly (84). 
Resistance to this drug occurs through inactivation by a type A chloramphenicol 
acetyltransferase, which can be transferred among bacterial strains (57,85). Finally, 
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despite the potential efficacy of vancomycin and linezolid against methicillin-resistant 
staphylococci (55), these drugs should not be used in veterinary medicine because of 
their importance for treating human MRSA infections (86).  
Zoonotic potential of MRSA and MRSP 
Several species, including humans, dogs, cats, horses, pigs, poultry, and some exotic 
animals, can serve as carriers for, and as sources of infection with, various strains of 
Staphylococcus (1,5,11,56). There are several misconceptions among clients and 
veterinarians regarding the implications of infection with MRSA or MRSP in dogs. It is 
also important to understand the difference between colonization with (i.e. carriage of) 
an organism and infection. Discriminating between MRSA and MRSP and 
understanding the applicable terminology is important for diagnostic reasons, for 
establishing the correct treatment protocol, and for protecting public health. 
MRSA 
Staphylococcus aureus is a leading cause of nosocomial infection in humans and is 
found in approximately 30% of healthy individuals in the United States (87). The US 
CDC defines a person as being colonized or having bacterial carriage when the bacteria 
is present without causing disease in the individual (88). This is in contrast to infection, 
in which an individual has clinical signs of disease. Fortunately, only a small proportion 
(< 2%) of healthy or asymptomatic individuals in the general population of the United 
States carry MRSA (87). Colonization can be transient or can become persistent, 
particularly in cases of repeated exposure. A person who lives in close contact with an 
MRSA-infected person can become persistently colonized with the same MRSA strain 
for months to years, and during this time they can serve as a source of secondary 
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 transmission to other individuals (89,90). The degree of risk appears to be related to 
closeness of exposure, because the risk of colonization for a spouse or child of a patient 
with MRSA is almost 7.5 times as great as that for a casual associate such as a friend or 
roommate (89).  
Staphylococcus aureus colonization in dogs is possible, but it is not common 
because the organism is not normally a component of the indigenous bacterial flora of 
dogs (58). The reported prevalence of S. aureus infection in dogs has ranged from 2 of 
24 (8.3%) (51) to 6 of 59 (10%) (49), whereas that of S. aureus carriage in healthy dogs 
has ranged from 2 of 43 (4.7%) (51) to 6 of 50 (12%) (49). Prevalence of MRSA is 
lower, with the organism isolated from 1 of 59 (1.7%) infected dogs in 1 study (49) and 
rates of carriage in healthy dogs as low as 0% found in studies that evaluated 50 dogs 
(49) and 200 dogs (91). Specific host and environmental conditions must be met for a 
dog to be exposed, become colonized, and serve as a potential reservoir for the organism 
while remaining apparently healthy. It has been suggested that MRSA infection or 
colonization in dogs results from transmission of the organism by humans (5,32,49,92). 
When identified in dogs, the MRSA strain most frequently isolated is USA100, which is 
a common cause of human hospital-acquired MRSA infections (1,31). Dogs used in pet 
therapy programs were shown to become contaminated with MRSA during hospital 
visits, suggesting that these animals could potentially serve as a means of transfer of 
MRSA from one human patient to another, thus spreading infection throughout a 
hospital (93).  
Interestingly, an association has been made between isolation of MRSA and 
employment within the veterinary profession (5,94). Rates of MRSA carriage in small 
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 animal hospital personnel (i.e., clinicians and technical staff) have been reported to range 
from 27 of 417 (6.5%) (95) to 59 of 341 (17.3%) (94), values that exceed the previously 
mentioned estimate of MRSA carriage in < 2% of healthy asymptomatic people in the 
United States (87). Carriage of MRSA in veterinary personnel may be attributable to 
contact with infected or colonized patients, particularly animals such as horses, in which 
S aureus is commonly part of the indigenous bacterial flora (5). To decrease the potential 
for transmission, veterinarians and veterinary staff should be educated about this 
occupational health risk and should consistently practice preventative measures, 
especially appropriate hand hygiene (96).  
MRSP 
Staphylococcus pseudintermedius is the most commonly encountered Staphylococcus 
species in the canine population and, unlike S. aureus, is part of the indigenous bacterial 
flora in dogs (97). In a study (10) in 2011 in which samples from dogs were collected 
with swabs in the waiting room area of a small animal hospital, investigators identified 
factors potentially associated with recovery of MRSP from dogs, including antimicrobial 
or corticosteroid treatment within the 6 months prior to culture, previous hospitalization, 
and entering a veterinary facility within the 4 weeks prior to culture. Results of the same 
study (10) revealed that 49 of 390 (12.6%) dogs treated with antimicrobials tested 
positive for MRSP, compared with 9 of 386 (2.3%) dogs that did not receive these drugs. 
This suggests that antimicrobial administration may potentially select for carriage of 
MRSP in dogs and supports the need for proper timing and selection of antimicrobial 
treatments. 
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 Unlike S. aureus, S. pseudintermedius is not a commensal organism in humans 
(98). Although infection does occur in humans, it appears to be uncommon and is 
usually associated with zoonotic transmission from a canine host (1,3,99-101). Our 
current understanding is that the overall importance of S. pseudintermedius as a zoonotic 
pathogen is less than that of MRSA (30). In humans, S. intermedius (S. pseudintermedius 
would have been identified as S. intermedius prior to 2005), infection was described in a 
few hospitalized patients in 1997 with a low prevalence (2/3,397 [0.06%]) (98). In a 
2010 study (1) that included several regions across the United States, the prevalence of 
MRSP carriage in veterinary dermatologists and their technical staff was found to be 9 
of 171 (5.3%). This was slightly lower than the 16 of 258 (6.2%) carriage rate in healthy 
dogs in the same study (1). Investigators in another study (101) showed that 6 of 13 
owners of dogs with deep pyoderma carried antimicrobial-resistant strains of S 
pseudintermedius identical to those recovered from their own dogs; the strains recovered 
from each dog-owner pair were distinct among the different households. This raises 
concerns that horizontal transfer of resistance genes may occur between antimicrobial-
resistant S. pseudintermedius and pathogenic strains of staphylococci carried by humans 
(101). At present, S. pseudintermedius rarely causes disease in humans, and the risk of 
transmission of MRSP from a pet to the owner should be evaluated on an individual 
basis (101).  
Infection control measures 
In-hospital practices 
Treatment of patients infected with methicillin-resistant staphylococci must incorporate 
prevention of nosocomial and zoonotic transmission. Consistent attention to hand 
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 hygiene  (i.e., using gloves, washing hands with soap and water after touching a patient 
(3,102), the use of alcohol pouches to clean hands when water is not available (102) has 
been repeatedly shown to be a protective factor against transmission, because 
staphylococcal infections are often spread through direct skin contact (5,32,56). Several 
studies (5,32,103,104) have shown that hospital personnel and equipment can serve as 
routes for transmission of infection. Investigators of a 2010 study (103) found that 66 of 
100 (66%) pens, 44 of 80 (55%) stethoscopes, 60 of 126 (47.6%) cell phones, and 37 of 
130 (28.5%) white coats used by physicians in a human hospital were contaminated with 
various bacteria. Staphylococcus spp were most commonly found, comprising 122 of 
436 (28%) isolates, and 9 (7.4%) of these were identified as MRSA.  
Staphylococci can survive for long periods in the environment. One study (104) 
showed that staphylococci were able to survive on a variety of fabric types and plastic 
materials in a human hospital, sometimes for > 90 days. In 1 veterinary teaching 
hospital, evaluation of environmental surface samples via DNA sequencing and PCR 
assay revealed that various cages, the top surfaces of a CT scan stand, a stand in a cat 
ward, and floors of the intensive care unit and MRI room were contaminated with MRSP 
(5). Routine disinfection of hospital surfaces and equipment as well as the use of 
stringent hand hygiene practices are critical to prevent or minimize the spread of 
infection. Most disinfectants are effective when applied to clean surfaces, and some 
quaternary ammonium compounds have been shown to retain antimicrobial activity for 
up to 48 hours (105).  
In addition to appropriate use of disinfectants and hand hygiene, the handling of 
infected patients should be limited to veterinary staff directly involved in their care to 
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 minimize the potential for transfer of organisms to other patients or staff members. 
Personal protective equipment should be worn to prevent contamination of clothing or 
body surfaces and transmission of bacteria to other patients or coworkers (106). This 
includes washable attire such as laboratory coats and disposable items such as gowns, 
gloves, or masks (106). Any patient with wounds should have those areas covered with a 
dressing to reduce environmental contamination, and soiled dressings should be disposed 
of properly (32) (i.e., in a trash bag kept near the patient’s cage and used solely for their 
contaminated waste or autoclaved as biological waste). Proper treatment and 
containment of the infection are the ultimate goals. Ideally, every hospital should have a 
formal written manual that delineates infection control procedures and guidelines, and an 
individual staff member should be assigned the task of ensuring that the program is 
understood and followed (106).  
Owner recommendations 
It has been shown that MRSP and MRSA can be transferred among humans and pets in 
households (56,99). Dogs known to have MRSP infections should not be allowed to 
share a bed with their owners, because this provides an opportunity for close contact and 
potential transfer of the organism (32). Similarly, humans with known MRSA infections 
should not allow a pet to lick their wounds or share their bed (32). Personal hygiene and 
environmental disinfection are vital in maintaining appropriate infection control in the 
home environment. Staphylococci can survive for days on fabric, vinyl, and plastic 
(107), and dust particles can preserve these organisms and also serve as source of 
contamination or infection (108). Cleaning and disinfection are appropriate measures for 
disrupting transmission and reinfection. However, the most important infection 
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 prevention measure is to consistently practice proper hand hygiene after handling a 
patient or contaminated material (106,109).  
Conclusions 
Because they are uniquely adapted commensal organisms, staphylococci are likely to 
remain a cause of opportunistic infection in humans and animals. Staphylococcal 
infections can range from simple skin infections and dermatologic disorders to severe 
systemic bacteremias that can cause multiorgan failure and death (33,42,51). For dogs 
with pyoderma, there are several key points that remain at the heart of successful 
treatment. Any underlying, predisposing conditions must be corrected or controlled as 
well as possible to provide the best opportunity for clinical resolution. Because 
pyoderma caused by antimicrobial-susceptible staphylococci is clinically 
indistinguishable than that caused by antimicrobial-resistant strains (67), patients that 
receive empirical treatment must be reevaluated during the treatment period to assess 
clinical response. When empirical treatment fails or infection reoccurs, culture and 
antimicrobial susceptibility testing of a sample should be performed to guide selection of 
an appropriate alternate antimicrobial drug. Finally, despite the potential efficacy of 
vancomycin and linezolid against methicillin-resistant staphylococci, these drugs should 
not be used in veterinary medicine because of their importance for treating human 
MRSA infections. Breaking the transmission cycle between humans and animals 
requires diligent hand hygiene and careful disinfection of the surfaces or materials on 
which staphylococci survive and proliferate. 
Additional research is needed to improve our understanding of S. 
pseudintermedius infection in dogs. Debate remains about whether there are differences 
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 between MRSA and MRSP infections in dogs with regard to severity of clinical signs 
and outcome. In general, it is thought that dogs are not preferred carriers of S. aureus 
and infection or colonization of dogs by MRSA results from transmission from humans 
(1,5,32). It is also thought that humans are not preferred carriers of S. pseudintermedius. 
Although this suggests that the potential for colonization or infection of the owner is 
generally low when a pet is identified as having an MRSP infection, this may not be the 
situation for immunocompromised owners (1,4), and each case should be evaluated 
individually. 
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 CHAPTER III 
CELL-WALL ASSOCIATED PROTEINS 
 
Introduction 
Staphylococcus pseudintermedius is the most frequent bacterial agent associated with 
pyoderma and secondary skin infection in dogs (1,2). Many dogs harbor  
S. pseudintermedius in their nares, oral cavity, and skin without clinical evidence of 
disease (1,3,4,42,100). Physical barriers, including intact epithelium and healthy mucous 
membranes, are generally sufficient to prevent infection with S. pseudintermedius. 
However, any condition that weakens the host’s ability to mount an immune response or 
that compromises these epidermal barriers can result in opportunistic S. 
pseudintermedius infections. This commonly occurs in dogs that have endocrinopathies 
(such as diabetes mellitus or hypothyroidism) (67), cornification disorders (110), or 
compromised immunity (111).  
Empirical treatment of staphylococcal infections such as pyoderma and 
secondary post-operative infection typically involves β-lactam antibiotics, such as 
cephalexin (9). Staphylococci that carry the penicillin binding protein 2a (PBP2a), 
encoded by the mecA gene, have a low affinity for all β-lactam antimicrobials and are 
considered methicillin-resistant (5,6,11,56-58). Methicillin-resistant S. pseudintermedius 
(MRSP) are increasingly resistant to other antimicrobials thus reducing treatment 
options for dogs with MRSP infections. In Europe, 90% of MRSP isolates are resistant 
to clindamycin, erythromycin, and trimethoprim, 70% are resistant to chloramphenicol 
and gentamicin, and 57% are resistant to chloramphenicol alone (2,10). In the United 
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States, resistance to fluoroquinolones and chloramphenicol in MRSP has become 
common, reducing antimicrobial options for treatment (11,12).  
Colonization or carriage of S. pseudintermedius on the skin requires adherence to 
epithelial surfaces, typically through tight attachment between host and bacterial 
proteins. The bacterial proteins involved are usually proteins on the outer surfaces of the 
bacteria, such as the outer membrane or cell wall proteins. A recent study identified 18 
cell-wall associated proteins (CWAPs) in S. pseudintermedius that are involved in 
attachment to host proteins (29). This study also showed that four of these 18 proteins 
(SpsF, SpsO, SpsP, and SpsQ) were present in only some isolates of S. pseudintermedius 
(29). It is not known whether there is any difference in the carriage of these proteins 
between isolates collected from healthy, asymptomatic dogs and dogs with clinical 
infection, or between isolates that are MRSP and MSSP. Determining which virulence 
factors are required for colonization and infection may allow development of novel 
strategies to reduce skin infection, including development of targeted therapeutics and 
rational design of staphylococcal vaccines.   
The objectives of this study were 1) to estimate the prevalence of the four 
variable CWAPs isolated from S. pseudintermedius; 2) to determine whether an 
association exists between these CWAPs and methicillin resistance; 3) to estimate the 
prevalence of methicillin-resistant S. pseudintermedius (MRSP); and, 4) to describe the 
susceptibility of MRSP to clindamycin, aminoglycosides, chloramphenicol, and 
fluoroquinolones. 
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Materials and methods 
Bacterial isolates 
A total of 374 canine S. pseudintermedius isolates collected at the Texas A&M 
University Veterinary Medical Teaching Hospital (VMTH) between September 2010 
and February 2012 were available for use in this study. All isolates were stored at -80oC 
at the time of collection and revived for this study by inoculating onto trypticase soy 
agar supplemented with 5% sheep blood (blood agar plates) (BD Diagnostic Systems, 
Franklin Lakes, NJ, USA). With the Institutional Animal Care and Use Committee’s 
(IACUC) approval, client-owned animals were swabbed for culture either upon entry 
into the hospital or when clinically warranted and divided into two populations based on 
health status (infected vs uninfected). Isolates from animals presented to the canine 
orthopedic surgery service that had no evidence of infection (i.e., clinically normal skin) 
were placed into the uninfected category for this study. Upon entry into the hospital, 
samples from the nares and perineum were collected separately from these patients using 
sterile swabs. Isolates derived from dogs that were presented for a clinical illness that 
required a bacterial culture for disease diagnosis were placed into the infected category. 
Specimens from this population were collected from the site of infection.  
Descriptive statistics 
Records of the 294 canine patients from which the 374 isolates had been obtained were 
analyzed retrospectively. Characteristics including breed, age, sex, presenting complaint, 
and concurrent diseases or diagnoses were recorded along with date of admission, date 
of discharge, and whether the dog was an inpatient or an outpatient. Culture and results 
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of antimicrobial drug minimum inhibitory concentration (MIC) testing were documented 
as was the number of days from hospital entry to time of culture.  
Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing on all isolates was performed according to the 
Clinical Laboratory Standards Institute (CLSI) guidelines (112) using commercially 
available systems (TREK Sensititre, TREK Diagnostics, Cleveland, OH, USA) and 
confirmed by oxacillin disk diffusion test on Mueller Hinton agar (BD Diagnostic 
Systems, Franklin Lakes, NJ, USA). As isolates were tested for antimicrobial 
susceptibility as part of patient care, the drugs tested varied (i.e., an isolate from a skin 
culture was tested with a different set of antimicrobial drugs than an isolate from a urine 
culture). The breakpoints provided in the CLSI veterinary standard (112) were used to 
determine whether an isolate was susceptible or resistant to an antimicrobial drug.  
mecA PCR 
Staphylococcus pseudintermedius isolates were tested for the presence of mecA by PCR 
using previously described primers (113) (M1, M2; Table 1) and methods (114) in the 
clinical microbiology laboratory of the VMTH at the time of original isolation. 
Staphylococcus aureus ATCC 43300 (methicillin-resistant) (ATCC, Manassas, VA, 
USA) and S. aureus ATCC 21923 (methicillin-susceptible) were used as control strains.  
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Table 1. Oligonucleotides used during this study. 
Primer (Constructed on) Protocol Significance Sequence, Reading 5’-3’ BP Size Reference 
M1 mecA mecA TGGCTATCGTGTCACAATCG 310 bp 113 M2 mecA CTGGAACTTGTTGAGCAGAG 113 
mA1 (mecA) SCCmec PCR 1 mecA TGCTATCCACCCTCAAACAGG 286 bp 115 mA2 (mecA) SCCmec PCR 1 AACGTTGTAACCACCCCAAGA 115 
α1 (ccrA1) SCCmec PCR 1 SCCmec type I AACCTATATCATCAATCAGTACGT 695 bp 115 
α2 (ccrA2) SCCmec PCR 1 SCCmec type II TAAAGGCATCAATGCACAAACACT 937 bp 115 
α3 (ccrA3) SCCmec PCR 1 SCCmec type III AGCTCAAAAGCAAGCAATAGAAT 1791 bp 115 
βc(ccrB1, ccrB2, ccrB3) SCCmec PCR 1 α1, 2, 3 reverse primer ATTGCCTTGATAATAGCCITCT 115 
α4.2 (ccrA4) SCCmec PCR 1 SCCmec type IV GTATCAATGCACCAGAACTT 1287 bp 115 
β4.2 (ccrB4) SCCmec PCR 1 TTGCGACTCTCTTGGCGTTT 115 
γR (ccrC) SCCmec PCR 1 SCCmec type V CCTTTATAGACTGGATTATTCAAAATAT 518 bp 115 
γF (ccrC) SCCmec PCR 1 CGTCTATTACAAGATGTTAAGGATAAT 115 
mI6 (mecI) SCCmec PCR 2 SCCmec type II or III* CATAACTTCCCATTCTGCAGATG 1963 bp 115 
IS7  (IS1272) SCCmec PCR 2 SCCmec type I or IV ATGCTTAATGATAGCATCCGAATG 2827 bp 115 
IS2(iS-2) (IS431) SCCmec PCR 2 SCCmec type V TGAGGTTATTCAGATATTTCGATGT 804 bp 115 
mA7 (mecA) SCCmec PCR 2 mI6, IS7, IS2 reverse primer ATATACCAAACCCGACAACTACA 115 
spsF-F Sps PCR Sps F AGTGGAAGCAACAGTTGAACGC 539 bp 29 spsF-R Sps PCR TGGACCTACTTGGCTACCACCA 29 
spsO-F Sps PCR Sps O GGTAGTGTATCAGTGCTAATAGGAGC 604 bp 29 spsO-R Sps PCR TTGACAAATCAGTAGCTGATGCAT 29 
spsP-F Sps PCR Sps P CAGGAGGACTAGGGTAATGTTCC 277 bp 29 spsP-R Sps PCR GCAAAACTTGGCGTGTTTACAAG 29 
spsQ-F Sps PCR Sps Q CCGCTCTATTTTTAGGTTAATC 593 bp 29 spsQ-R Sps PCR GCGCTTCATCGAAACTTGGCGCAGG 29 
R20 Sps sequencing CAGCTATGACCATGATTACG 165 bp + Sps gene bp U19 GTTTTCCCAGTCACGACGT 
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SCCmec typing 
MRSP isolates were inoculated on blood agar plates and incubated at 37°C for 24 h. A 
single colony was used to inoculate 10 ml of LB broth and incubated at 37oC overnight. 
DNA was purified from the broth culture using a DNeasy Blood & Tissue Kit (Qiagen, 
Germantown, MD, USA) according to the manufacturer’s instructions for gram-positive 
bacteria. DNA concentration was quantified using a NanoDrop™ ND-1000 
spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). 
SCCmec typing was performed by PCR to distinguish between SCCmec types I 
to VI.  SCCmec PCR 1 amplification was carried out as a multiplex PCR in a 50 μL 
reaction volume that consisted of 1X storage buffer (20 mM Tris-HCl [pH 8.0], 100 mM 
KCl, 0.1 mM EDTA, 1 mM DDT, 0.5% Polysorbate 20, 0.5% Nonidet P-40, 50% 
glycerol), 3.2 mM MgCl2, 0.2 mM each deoxynucleoside triphosphate (Life 
Technologies, Grand Island, NY, USA), 10 pmol of each previously described primer 
(115) (mA1, mA2, α1, α2, α3, βc, α4.2, β4.2, γR, γF, mI6, IS7, IS2, mA7; Table 1), 1.25 
U of TaKaRa Ex Taq DNA polymerase (Clontech Laboratories, Otsu, Shiga, Japan), and 
100 ng of purified bacterial DNA. The PCR assays were performed using an Applied 
Biosystems 2720 Thermal Cycler (Life Technologies, Grand Island, NY, USA) with an 
initial 2 min denaturation step at 94°C, followed by 30 cycles consisting of a 2 min 
denaturation step at 94°C, a 1 min annealing step at 57°C, a 2 min extension at 72°C, 
and a final extension step for 2 min at 72°C (115). SCCmec PCR 2 amplification was 
carried out as a multiplex as described for SCCmec PCR1 with the alteration of the 
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annealing temperature to 60°C (115). PCR products were visualized using UV light and 
documented with a digital imaging system (Fluoro Chem, Alpha Innotech, Santa Clara, 
CA, USA) after electrophoresis on a 1% (wt/vol) agarose gel (Phenix Research Products, 
Candler, NC, USA) containing 0.1 μL GelRed Nucleic Acid Gel Stain 10,000X 
(Biotium, Inc., Hayward, CA, USA) per ml of gel. Two molecular weight ladders, 100 
bp and 1 kb plus, (Life Technologies, Grand Island, NY, USA) were used to compare 
PCR product sizes. S. aureus ATCC 43300 (ATCC, Manassas, Virginia, USA), S. 
aureus ATCC 21923, and S. aureus ATCC 25932 were used as controls. All primers 
were synthesized by Sigma-Genosys, The Woodlands, TX, USA. 
sps gene PCR and gel electrophoresis 
PCR amplification of the sps genes was carried out as single PCR reactions using 50 μL 
mixtures that consisted of 1X storage buffer (10 mM KCl, 0.01mM EDTA, 0.1mM 
DTT, 5% glycerol, 0.01% Triton X-100), 2 mM MgCl2, 0.25 mM each deoxynucleoside 
triphosphate (Life Technologies, Grand Island, NY, USA), 20 pmol of each previously 
described primer (29) (spsF-F, spsF-R, spsO-F, spsO-R, spsP-F, spsP-R, spsQ-F, spsQ-
R; Table 1), 2.5 U of Econo Taq polymerase (Lucigen, Middleton, WI, USA), and 1 
colony of bacteria grown on blood agar plates. The PCR assays were performed using an 
Applied Biosystems 2720 Thermal Cycler with an initial 2 min denaturation step at 
95°C, followed by 30 cycles consisting of a 20 s denaturation step at 95°C, a 20 s 
annealing step at 50°C, a 2 min extension at 72°C, and a final extension step for 3 min at 
72°C (29). PCR products were visualized using UV light and documented with a digital 
imaging system after electrophoresis on 1% (wt/vol) agarose gel containing 0.1 μL 
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GelRed Nucleic Acid Gel Stain 10,000X per ml of gel. A 100 bp molecular weight 
ladder was used compare product sizes (Life Technologies; Grand Island, NY, USA). 
Confirmation of sps gene PCR product sequence 
sps gene PCR products were purified using a Wizard SV Gel and PCR Clean-Up System 
(Promega, Madison, WI, USA) according to the manufacturer’s instructions. Purified 
DNA fragments were cloned using the pT7Blue Perfectly Blunt Cloning Kit (Novagen, 
EMD Millipore, Billerica, MA, USA) according to the manufacturer’s instructions and 
transformed into chemical competent E. coli NovaBlue cells (Novagen, EMD Millipore, 
Billerica, MA, USA). These cells were plated on LB agar (116) with 40 μg/mL x-gal 
(Roche, Indianapolis, IN, USA) and 100 μg/mL carbenicillin (Teknova, Hollister, CA, 
USA). White colonies were tested using primers R20 and U19 for the presence of an 
appropriately sized insert. Colonies that were positive for the insert by PCR were 
inoculated into 4 mL of LB broth for overnight culture at 37oC and plasmid DNA was 
isolated with a QIAprep Spin MiniPrep Kit (Qiagen, Germantown, MD, USA) according 
to the manufacturer’s instructions. Plasmid DNA was quantified using a NanoDrop ND-
1000 Spectrophotometer. DNA sequencing was then performed using the R20 primer. 
The resultant sequences were compared with the known sequence for these genes from 
ED99 available in GenBank as NC_017568.1 (40). 
Statistical analysis 
Data were analyzed using mixed-effects logistic regression to determine the association 
between methicillin resistance status (MRSP versus MSSP) of the isolate and individual 
variables of the dog from which they were isolated such as age and breed. Because some 
dogs contributed more than 1 isolate, dog was modeled as a random effect. All variables 
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 associated with MRSP at a significance level of P < 0.1 were included in a multivariable 
random effects logistic regression modeling approach. A purposeful step-wise 
elimination process was used in which all variables were included in the model. 
Variables were eliminated from the model if their coefficient did not remain 
significantly associated with disease. All pair-wise interactions were examined for 
retained variables. The association between MRSP and other variables was summarized 
as the odds ratio (OR), and the 95% confidence limit (95% CI) for the OR, estimated 
using maximum likelihood methods.  Models were fit using the glme function of S-
PLUS statistical software (Version 8.2, TIBCO, Inc., Seattle, WA). Model fit was 
assessed by examining diagnostic plots of residuals.  Comparisons of categorical 
variables summarized as simple proportions were made using chi-squared analysis using 
S-PLUS. Significance level for all statistical analyses was P < 0.05.  
Results 
Age 
The ages of the dogs from which MRSP was isolated were similar (median, 6 years; 
range, 0.2 to 15 years) to those of dogs with MSSP (median, 6 years; range, 0.5 to 16 
years The proportion of MRSP isolates that were from dogs > 5 years of age (59%; 
41/69) was similar (P = 0.7460) to that for MSSP isolates (56%; 172/305).  
Breed 
There were 79 distinct breeds of dogs reported. Isolates were most common from dogs 
of the following breeds: Labrador Retriever (n = 56 isolates); German Shepherd Dog (n 
= 31); mixed-breed (n = 33); Golden Retrievers (n = 17); Bulldog-type (n = 17); 
Miniature Schnauzer (n = 12); Boxer (n = 10); and Yorkshire Terrier (n = 9). However, 
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 breed was not significantly associated with MRSP. Breed was also examined using the 
AKC breed groupings of Sporting, Hound, Working, Terrier, Toy, Non-Sporting, and 
Herding, with an additional group creating for mixed-breed. Although there was no 
significant difference in carriage of MRSP between groups, dogs in the Toy group 
tended to be less likely to have MRSP (P = 0.0549; Table 2). 
Sex 
There was no significant difference in the proportion of isolates that were cultured from 
female dogs versus male dogs (P = 0.7200), and the odds of an isolate coming from 
female dogs (relative to male dogs) were not significantly greater (P = 0.6186) for the 
MRSP group than the MSSP group (OR = 0.9; 95% CI, 0.5 to 1.5).  
Patient hospitalization 
There was no significant association between MRSP and whether isolates came from 
dogs that were inpatients or outpatients. The proportion of isolates that came from 
inpatients was similar among MRSP isolates (57%; 39/69) and MSSP isolates (54%; 
166/305; P = 0.8556), and the odds of an isolate coming from an inpatient dog (relative 
to outpatient dogs) were not significantly greater (P = 0.75) for the MRSP group than the 
MSSP group (OR = 1.1; 95% CI, 0.7 to 1.9). Most isolates (81%; 304/374) were 
collected from dogs on the day of admission (days in hospital = 0). The proportion of 
isolates that were collected after day 0 was significantly (P < 0.0001) greater for the 
MRSP isolates (36%; 25/69) than for the MSSP isolates (15%; 45/305; Table 2); the 
maximum value was 18 days for the MRSP and 34 days for the MSSP. 
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 Table 2. Variables significantly associated with the MRSP colonization status of individual dogs (n = 294) from which 
isolates of Staphylococcus pseudintermedius (n =374) were obtained.* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Bolded items were significantly associated with MRSP isolates and underlined items had approached the threshold of 
statistical significance associated with isolates from MSSP.
Variable MRSP MSSP Odds Ratio (95% CI) P-value 
AKC group 
    Mixed breed 8/69 (12%) 25/305 (8%) 1 NA 
    Sporting 22/69 (32%) 69/305 (23%) 0.9 (0.4 to 2.4) 0.9939 
    Hound (3/69 (4%) 28/305 (9%) 0.3 (0.1 to 1.4) 0.1323 
    Working 10/69 (14%) 35/305 (11%) 0.9 (0.3 to 2.6) 0.8343 
    Terrier 9/69 (13%) 30/305 (10%) 0.9 (0.3 to 2.8) 0.9076 
    Toy 4/69 (6%) 44/305 (14%) 0.3 (0.1 to >1.0) 0.0549 
    Non-Working 4/69 (6%) 25/305 (8%) 0.5 (0.1 to 1.9) 0.3045 
    Herding 9/69 (13%) 49/305 (16%) 0.6 (0.2 to 1.7) 0.3084 
     
Samples collected after day of admission (day 0 of hospitalization) 
    No 44/69 (64%) 260/305 (85%) 1 NA 
    Yes 25/69 (36%) 45/305 (15%) 3.3 (1.8 to 5.9) <0.0001 
     
Disease status 
    Healthy 13/69 (19%) 168/305 (55%) 1 NA 
    Diseased 56/69 (81%) 137/305 (45%) 5.5 (2.8 to 10.1) <0.0001 
     
Source (Including nasal and perineal) 
    Nasal or perineal skin 13/69 (19%) 172/305 (56%) 1 NA 
    Other skin (pyoderma, wounds, etc…) 32/69 (46%) 79/305 (26%) 5.4 (2.7 to 10.8) <0.0001 
    Urine 12/69 (17%) 25/305 (8%) 6.4 (2.6 to 15.5) <0.0001 
    Other non-skin sources 12/69 (17%) 29/305 (10%) 5.5 (2.3 to 13.2) <0.0001 
     
Source (skin excluding nasal and perineal isolates) 
    Pyoderma 17/32 (53%) 35/79 (44%) 3.1 (0.8 to 11.8) 0.1051 
    Wounds 12/32 (38%) 25/79 (32%) 3.0 (0.8 to 12.3) 0.1219 
    Other skin 3/32 (9%) 19/79 (24%) 1 NA 
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 Isolate source 
There were 22 distinct anatomic sites or tissues from which the isolates were cultured. 
The most common site of origin of isolates was the skin (n = 296) followed by urine (n = 
37), bone (n = 9), bladder stones or bladder mucosa (n = 8), and other sources (n = 41). 
The 296 isolates that came from skin sources included 104 from the perineum, 81 from 
the nares, 52 from pyoderma, 37 from wounds, 8 from ears, 8 from incisional infections, 
5 from tumors, and 1 from an implant infection that resulted in a draining tract through 
the skin. Because the proportion of isolates that were MRSP was the same for both nasal 
(7%; 6/81) and perineal isolates (7%; 7/104), and because these isolates were collected 
primarily from dogs with healthy skin examined by the orthopedic service, the nasal and 
perineal categories were collapsed. For analysis, the other skin sources were regrouped 
to pyoderma, wounds, and other skin sources. There was a significant association 
between source and MRSP (Table 2). All other skin sources were significantly (P < 
0.0001) more likely to yield MRSP than nasal or perineal isolates, with similar 
magnitude of ORs compared to MSSP. However, when restricting analyses to the 111 
isolates from skin sources other than nasal and perineal, there was no significant 
association of MRSP with skin source. Isolates that were methicillin-resistant were 
significantly (P < 0.0001) more likely to be associated with isolates from dogs with 
disease (Table 2). 
Antimicrobial resistance 
Of the 374 isolates in this study, 69 (18%) were methicillin-resistant based on oxacillin 
resistance as measured by microbroth dilution (MIC ≥ 0.5 µg/ml), disk diffusion test 
(zone of inhibition ≤ 17mm), and PCR for the mecA gene (Figure 1). Aside from β-
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 lactam drugs, MRSP isolates were more likely to be resistant to antimicrobial drugs than 
MSSP isolates (Figure 1, P = <0.0001). There were only three drugs to which more than 
50% of the MRSP isolates were susceptible: amikacin (70%), chloramphenicol (55%), 
and gentamicin (52%) (Figure 1).   
 
 
Figure 1. Antimicrobial resistance patterns associated with MRSP and MSSP isolates of 
Staphylococcus pseudintermedius (N= 374).a Bar graphs compare isolates of MSSP (top 
row; n = 305) and MRSP (bottom row; n = 69) that are susceptible, intermediate, or 
resistant to nine non-β-lactam antibiotics. Color differentiation is as follows: black = 
resistant isolates; grey = intermediate isolates; white = susceptible isolates. 
Antimicrobial susceptibility of MRSP and MSSP to all nine of these drugs was 
statistically significant with a P-value <0.0001. aMIC breakpoints from the Clinical and 
Laboratory Standards Institute were used to determine category (112). 
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 SCCmec type 
The 69 MRSP isolates were SCCmec typed by PCR. The SCCmec typing PCR used in 
this study can distinguish SCCmec types I-VI. Currently, there are 11 established 
SCCmec types (117). Of the 69 isolates, 44 (64%) were type V, nine (13%) were type 
III, six (9%) were type IV, five (7%) had an unknown PCR product pattern that could 
not be typed by the multiplex PCR utilized in this study, and 1 MRSP isolate (1%) was 
from a healthy dog that was mecA positive but had no visible SCCmec PCR products 
despite repeated PCR attempts. In addition, there were four isolates that had multiple 
SCCmec types. For each of these four isolates, the isolate contained SCCmec type V in 
addition to another SCCmec type. 
sps genes-single genes 
Isolates were screened by PCR to determine whether they carried any of the genes 
encoding the four CWAPs of interest. Of the 374 isolates, 70 (19%) carried the spsF 
gene, 35 (9%) carried the spsO gene, 64 (17%) carried the spsP gene, and 72 (19%) 
carried the spsQ gene (Table 3). Of these genes, only spsP and spsQ were significantly 
associated with methicillin resistance (Table 3). The proportion of spsP-bearing isolates 
was significantly (P = 0.0006) greater among MRSP isolates (32%; 22/69) than among 
MSSP isolates (14%; 42/305). The odds of an isolate having spsP (relative to another sps 
gene) were significantly greater (P = 0.0005) for the MRSP group than the MSSP group 
(OR = 2.9; 95% CI, 1.6 to 5.4). The proportion of spsQ-bearing MRSP isolates (35%; 
24/69) was also significantly greater (P = 0.0006) than the proportion of spsQ-bearing 
MSSP isolates (16%; 48/305). The odds of an isolate having spsQ (relative to another  
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 Table 3. sps genes associated with methicillin-resistant Staphylococcus pseudintermedius (n = 374).* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Those marked in bold were significantly associated with methicillin-resistant isolates. 
**Odds ratio was incalculable because no MRSP isolates carried these gene combinations. 
ND = Not Determined 
sps Gene MRSP MSSP Odds Ratio (95% CI) P-value 
Individual Genes     
    spsF 15/69 (22%) 55/305 (18%) 1.2 (0.7 to 2.5) 0.4755 
    spsO 5/69 (7%) 30/305 (10%) 0.7 (0.3 to 1.9) 0.5069 
    spsP 22/69 (32%) 42/305 (14%) 2.9 (1.6 to 5.4) 0.0005 
    spsQ 24/69 (35%) 48/305 (16%) 2.8 (1.6 to 5.1) 0.0005 
Two Genes     
    spsF and spsO 2/69 (3%) 11/305 (4%) 0.8 (0.2 to 3.7) 0.7725 
    spsF and spsP 2/69 (3%) 10/305 (3%) 0.9 (0.2 to 4.1) 0.8716 
    spsF and spsQ 4/69 (6%) 11/305 (4%) 1.6 (0.5 to 5.3) 0.4072 
    spsO and spsP 0/69 (0%) 5/305 (2%) **Incalculable ND 
    spsO and spsQ 0/69 (0%) 6/305 (2%) **Incalculable ND 
    spsP and spsQ 20/69 (29%) 37/305 (12%) 3 (1.6 to 5.5) 0.0007 
Three Genes     
    spsF and spsO and spsP 0/69 (0%) 3/305 (1%) **Incalculable ND 
    spsF and spsO and spsQ 0/69 (0%) 3/305 (1%) **Incalculable ND 
    spsF and spsP and spsQ 2/69 (3%) 9/305 (3%) 1.0 (0.2 to 4.8) 0.9815 
    spsO and spsP and spsQ 0/69 (0%) 3/305 (1%) **Incalculable ND 
All Genes     
    spsF and spsO and spsP and spsQ 0/69 (0%) 2/305 (1%) **Incalculable ND 
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 sps gene) were significantly greater (P = 0.0005) for the MRSP group than the MSSP 
group (OR = 2.8; 95% CI, 1.6 to 5.1).  
sps genes-pairwise comparisons 
Some isolates carried more than one of the four genes. There was no difference in rates 
of carriage of multiple genes between MRSP and MSSP except for isolates carrying both 
spsP and spsQ (Table 3). The proportion of isolates positive for both spsP and spsQ was 
significantly (P = 0.0009) greater among MRSP isolates (29%; 20/69) than among 
MSSP isolates (12%; 37/305); and the odds of an isolate having both spsP and spsQ 
(relative to isolates having neither gene or having only spsP or only spsQ) were 
significantly greater (P = 0.0007) for the MRSP group than the MSSP group (OR = 3.0; 
95% CI, 1.6 to 5.5).  
sps genes-multiple genes 
It was only possible to calculate ORs of differences between carriage of 3 or more 
CWAP genes in MRSP and MSSP for the combination of spsF, spsP, and spsQ as none 
of the other gene combinations were present in MRSP isolates, making the OR 
incalculable (Table 3). Eleven isolates were positive for the spsF, spsP, and spsQ genes. 
The proportion of isolates positive for these 3 genes was similar (P = 0.7104) between 
MRSP isolates (3%; 2/69) and MSSP isolates (3%; 9/305); and the odds of an isolate 
having spsF, spsP, and spsQ (relative to isolates not having all 3) were not significantly 
greater (P = 0.9815) for the MRSP group than the MSSP group (OR = 1.0; 95% CI, 0.2 
to 4.8).  
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 sps genes vs. source 
There was no association between any individual sps gene or combination of genes and 
isolation of S. pseudintermedius from pyoderma or wounds although isolates with more 
than two genes came predominantly from dogs with pyoderma (12%; 6/52) as compared 
with dogs with wounds (3%; 1/37) or other skin sources (5%; 1/22). The nasal and 
perineal skin isolates were excluded from analysis because they were collected from 
dogs presenting to only one hospital service which resulted in a confounding effect.  
Discussion  
There were a number of clinically relevant findings from this study. The first is that 
there was a strong association between methicillin resistance in S. pseudintermedius 
isolates and infection (Table 2).This was true for skin, urine, and other sites of infection. 
Among the MRSP isolates tested here, we found that 70% (47/67) were susceptible to 
amikacin and 55% (38/69) were susceptible to chloramphenicol, but fewer were 
susceptible to other drugs such as marbofloxacin (31%; 21/67) and enrofloxacin (25%; 
17/69) (Figure 1). These findings may reflect the patient population of our hospital 
which includes both primary-care patients and patients referred to specialty services 
(such as dermatology and orthopedic surgery). As a referral practice, it is common to 
receive patients with infections that have failed to respond to empiric antimicrobial 
therapy. Prior antimicrobial therapy is a risk factor for establishment of carriage (10) and 
infections (118) with MRSP and may explain the occurrence of antimicrobial resistance 
among the studied isolates. Prior exposure to antimicrobial drugs was not included in all 
patient histories. Consequently, we were unable to evaluate whether prior antimicrobial 
use was associated with our finding linking methicillin-resistance and infection.   
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 Methicillin-resistant staphylococci are identified phenotypically through 
antimicrobial susceptibility testing and genetically through the detection of mecA, a gene 
that confers resistance to all β-lactam drugs and that is carried on a transmissible mobile 
DNA element called SCCmec (11). SCCmec contains the mec gene complex consisting 
of mecA, the genes that control expression of the mecA gene, and unique site-specific 
recombinases called cassette chromosome recombinases (ccr) (11). Once established, 
SCCmec types tend to dominate specific geographical regions and can be used to 
perform epidemiologic studies and monitor disease patterns (8). Our finding that 64% of 
all isolates possessed SCCmec type V was consistent with other published data which 
showed that in North America SCCmec type V is the dominating clonal lineage (11). 
Currently, there are as many as 11 SCCmec types reported in the literature (117). Six of 
our isolates were either untypable or had banding patterns that were not recognized by 
the multiplex utilized in this study despite repeated PCR attempts. Because the multiplex 
used in this study only recognized SCCmec types I to VI but all isolates carried mecA, 
we hypothesize that these six isolates are among SCCmec types VII to XI.  Sequencing 
of the SCCmec of these isolates would resolve the question of type but was not 
undertaken in this study. 
Increased prevalence of MRSP and increasing prevalence of MRSP resistant to 
all classes of antimicrobial drugs, including aminoglycosides, have led to the search for 
alternatives to antimicrobial therapy including vaccines. In theory, a successful 
staphylococcal vaccine would prevent bacterial adherence or promote immune mediated 
killing of the bacteria (119,120). Such vaccines would naturally target outer membrane 
proteins of the bacteria. For S. pseudintermedius, surface antigen expression and 
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 variation was recently described among the cell-wall-anchored proteins SpsD and SpsO 
(121). Antibodies to SpsD and SpsL were identified in canine pyoderma patients, 
indicating that these bacterial proteins induce a humoral immune response (29). In this 
study, there was a significant association with spsP and spsQ with MRSP and of MRSP 
with infection. Together, these findings suggest a role for the proteins encoded by these 
genes during infection. SpsP and SpsO may offer an attractive target for future 
staphylococcal vaccines against MRSP. It was not surprising that spsP and spsQ were 
associated with each other as both genes are located adjacent to each other near oriC on 
the S. pseudintermedius chromosome and have been shown previously to have 67 to 
90% sequence identity in any pairwise alignment (29). 
This study is limited by its retrospective nature. Patient histories were obtained 
through examination of the medical records. Some cases may have had previous cultures 
or prior antimicrobial treatment that were not noted in the records or not identified 
during the study period. Another limitation of the study was the sampling strategy. The 
healthy control population consisted of dogs admitted to the orthopedic service that had 
specimens collected from the nares and perineum for a separate study. Almost all nasal 
and perineal samples in the present study were from this population; thus, skin source 
was strongly associated with disease status. Because isolation of MRSP was strongly 
associated with disease status, it appeared that MRSP was strongly associated with skin 
sources other than nasal and perineal; however, when swabs from the nasal and perineal 
region were excluded, swabs of sites of infection or pyoderma were not significantly 
associated with MRSP (Table 2). Future studies should use unbiased sampling design to 
avoid problems of selection bias and confounding.  
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 In this study, MRSP was strongly associated with clinical disease. While there 
was no significant difference between sps gene and source in this study it is interesting 
that the majority of isolates with multiple genes were from dogs that had pyoderma. In 
addition, spsP and spsQ were significantly associated with methicillin resistance. This 
new information may impact the development of S. pseudintermedius vaccines or 
alternative therapies for staphylococcal infections in dogs. 
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 CHAPTER IV 
AMIKACIN RESISTANCE GENES∗ 
 
Introduction 
Staphylococcus pseudintermedius is the most common bacterial agent isolated from 
canine pyoderma and wound infections in dogs (1,2). Treatment of staphylococcal 
infection typically involves therapy with β-lactam antibiotics such as penicillin and 
cephalosporins. Resistance to this class of antimicrobial drug has increased in recent 
years, associated with the rise in methicillin resistance in S. pseudintermedius (55). In 
addition to being resistant to β-lactam antimicrobials, methicillin-resistant S. 
pseudintermedius (MRSP) strains are increasingly resistant to other antimicrobials (15). 
A multi-center study from Europe and North America showed that MRSP isolates are 
commonly resistant to virtually all antimicrobial drug classes approved for use in dogs 
with 90% of MRSP isolates resistant to ciprofloxacin, clindamycin, erythromycin, 
kanamycin, streptomycin, and trimethoprim, while 57% were resistant to 
chloramphenicol (2,10). Decreased susceptibility of MRSP to other antimicrobials has 
left relatively few options for therapy. Data for North America are limited but many 
North American MRSP isolates were previously susceptible to chloramphenicol, 
rifampin, and amikacin. We have isolated MRSP that are resistant to chloramphenicol 
and have begun to identify isolates resistant to amikacin at our hospital (Table 4).  
∗Reprinted with permission from “Amikacin resistance in Staphylococcus 
pseudintermedius isolated from dogs” by Gold RM, Cohen ND, Lawhon SD, 2014. 
Journal of Clinical Microbiology, 52, 3641-3646, Copyright [2014] by American 
Society for Microbiology. 
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 Table 4.  Amikacin-resistant and chloramphenicol-resistant Staphylococcus 
pseudintermedius isolates collected from the Texas A&M Veterinary Medical Teaching 
Hospital (VMTH), 2010-2012. 
 2010 2011 2012 
Total S. pseudintermedius isolates 186 292 212 
Amikacin-resistant S. pseudintermedius isolates*  5 30 37 
Percentage of amikacin-resistant S. pseudintermedius isolates  2.7% 10.3% 17.5% 
Chloramphenicol-resistant S. pseudintermedius isolates**  8 48 45 
Percentage of chloramphenicol-resistant S. pseudintermedius isolates  4.3% 16.4% 21.2% 
 
*Isolates with an amikacin minimum inhibitory concentration ≥ 64µg/ml were 
considered resistant. 
**Isolates with a chloramphenicol minimum inhibitory concentration ≥ 16µg/ml were 
considered resistant. 
 
 
 
 Aminoglycosides like amikacin inhibit bacterial protein synthesis by binding to 
the 30S ribosomal subunit (13). The most widespread mechanism of aminoglycoside 
resistance is drug inactivation by cellular aminoglycoside modifying enzymes (AMEs) 
encoded on the chromosome, a plasmid, or carried on a transposable element (14,17). 
They can be divided into three classes: aminoglycoside acetyltransferases (AACs), 
aminoglycoside (phosphotransferases (APHs), and aminoglycoside 
nucleotidyltransferases (ANTs) (18). In S. aureus, the aac(6′)/aph(2′′) gene is the most 
frequently encountered aminoglycoside resistance gene followed by aph(3′)- IIIa and 
ant(4′)-Ia (18,19).  
The purpose of this study was to determine which genes encoding amikacin 
modifying enzymes are present in amikacin-resistant S. pseudintermedius isolates 
collected from canine patients using a previously described multiplex polymerase chain 
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 reaction (PCR) assay (18), and to see if an association exists between amikacin 
resistance, methicillin resistance, and resistance to non-β-lactam antibiotics. Although 
amikacin resistance has been noted in S. pseudintermedius and studies of 
aminoglycoside resistance in S. aureus have been published, no studies have assessed 
aminoglycoside resistance gene carriage in S. pseudintermedius (14,18,19,122).  
Staphylococcus pseudintermedius is commonly associated with canine pyoderma and 
post-operative wound infections (1,2). Amikacin resistance in S. pseudintermedius has 
significant repercussions for the treatment of canine MRSP infections particularly as 
resistance to other classes of antimicrobial drugs, like fluoroquinolones, limits 
antimicrobial choices for treatment. Understanding which aminoglycoside resistance 
mechanisms are present in S. pseudintermedius is crucial to the development of 
strategies to prevent resistance to this last line of therapy. 
Materials and methods 
Bacterial isolates 
A total of 422 canine Staphylococcus pseudintermedius isolates collected from the Texas 
A&M Veterinary Medical Teaching Hospital (VMTH) between 2010-2012 were 
available for study. All isolates were cultured from patient specimens by technicians in 
the VMTH Clinical Microbiology Laboratory according to the standard operating 
procedures of the laboratory. Antimicrobial susceptibility was performed according to 
the CLSI standards (63) using a commercially available system (TREK Sensititre, TREK 
Diagnostics, Cleveland, OH, USA). In this study, isolates with intermediate 
susceptibility based on the CLSI interpretive criteria were considered to be resistant to 
the antimicrobial drug tested (63). 
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 To identify methicillin resistance, every isolate was evaluated by three tests; 
oxacillin microbroth dilution test, oxacillin disk diffusion test, and PCR for detection of 
mecA. The oxacillin breakpoints used to confirm methicillin-resistance were minimum 
inhibitory concentration (MIC) ≥ 0.5 μg/ml and disk diffusion zone of inhibition ≤17 
mm. These breakpoints were adopted by the Clinical Microbiology Laboratory following 
recognition that the CLSI Standards published in 2008 failed to identify some MRSP 
isolates (62,65). All three tests were performed on every isolate. Any isolate in which at 
least two of the three tests indicated methicillin resistance was deemed MRSP. PCR was 
performed using previously described primers (113) and methods (114), with S. aureus 
ATCC 43300 and S. aureus ATCC 21923 used as positive and negative controls, 
respectively (ATCC, Manassas, Virginia, USA). Disk diffusion and microbroth dilution 
tests were performed in accordance with the CLSI Performance Standards (63). 
Amikacin susceptibility of staphylococcal isolates was not routinely tested in the 
Clinical Microbiology Laboratory prior to 2010. As such, only isolates collected 
between October 22, 2010 and December 31, 2012 were included in this study.  From 
this inclusion period, two datasets were generated. Dataset 1 included 422 isolates that 
were tested for amikacin resistance. This dataset was used to determine the prevalence of 
amikacin resistance and the association of amikacin resistance with resistance to other 
antimicrobial drugs. A second dataset included only the 32 amikacin-resistant isolates 
from dataset 1 that were available for further testing. The isolates in the second dataset 
were analyzed by PCR for the presence of resistance genes that encode aminoglycoside 
modifying enzymes. 
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 Amikacin disk diffusion 
Isolates not tested for amikacin resistance at the time of initial culture (i.e., antimicrobial 
susceptibilities originally performed on isolates from urine) were screened for amikacin 
resistance by disk diffusion. The disk diffusion tests were performed according to the 
Clinical and Laboratory Standards Institute (CLSI) Performance Standards (63).  Isolates 
with a zone of inhibition ≤ 14 mm were considered resistant to amikacin.  
DNA isolation and purification 
Of the 422 initial isolates, 32 of the total 53 amikacin-resistant isolates were available 
for genetic testing. All isolates were stored at -80oC at the time of collection and revived 
by inoculating them onto trypticase soy agar supplemented with 5% sheep blood (blood 
agar plates) (BD Diagnostic Systems, Franklin Lakes, NJ, USA) and incubated at 37°C 
for 24 hr. A single colony was used to inoculate 10 ml of L-broth (LB) which contained 
10g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl2 and incubated at 37oC overnight. 
The LB components were supplied by BD Diagnostic Systems, Franklin Lakes, NJ, USA 
(tryptone and yeast extract) and Mallinckrodt Chemicals, St. Louis, MO, USA (NaCl2). 
DNA was purified from the broth culture using a DNeasy Blood & Tissue Kit (Qiagen, 
Germantown, MD, USA) according to the manufacturer’s instructions for Gram positive 
bacteria. DNA was quantified using a NanoDrop™ ND-1000 spectrophotometer 
(Thermo Fisher Scientific Inc., Waltham, MA, USA). 
Polymerase chain reaction 
Previously published primers for aac(6’)/aph(2”) (5′-GAAGTACGCAGAAGAGA-3′; 
5′-ACATGGCAAGCTCTAGGA-3′), aph(3’)-IIIa (5′-AAATACCGCTGCGTA-3′; 5′-
CATACTCTTCCGAGCAA-3′), ant(4’)-Ia (5′-AATCGGTAGAAGCCCAA-3′; 5′-
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 GCACCTGCCATTGCTA-3′) and mecA (5′-CCTAGTAAAGCTCCGGAA-3′; 5′-
CTAGTCCATTCGGTCCA-3′) were used to generate PCR products of 491, 242, 135, 
and 314 base pairs respectively  (Sigma-Aldrich, St. Louis, MO, USA) (18). PCR 
amplification was carried out as previously described using 50-µL mixtures containing 
0.2 µM forward and reverse primers, 1× Taq buffer, 3 mM MgCl2, 0.2 mM (each) 
deoxynucleoside triphosphate, 1 U of Ex Taq DNA polymerase, and inoculation with 2 
µl of purified chromosomal template DNA. All PCR reagents were supplied by Takara 
Bio Company, Otsu, Shiga, Japan. The PCR assays were performed using an Applied 
Biosystems 2720 Thermal Cycler (Life Technologies, Grand Island, NY, USA) with an 
initial 5 minute denaturation step at 95oC, followed by 30 cycles consisting of a 2 minute 
denaturation step at 95°C, a 30 second annealing step at 58°C, a 30 second extension at 
72°C, and finishing with a final extension step for 7 minutes at 72oC as previously 
described (18). PCR products were visualized using UV light and documented with an 
digital imaging system (Fluoro Chem, Alpha Innotech, Santa Clara, CA, USA) following 
electrophoresis on 1% (wt/vol) agarose gel (Phenix Research Products, Candler, NC, 
USA) containing 0.1 μl GelRed Nucleic Acid Gel Stain 10,000× (Biotium, Hayward, 
CA, USA) per ml of gel. The 1 kb Plus™ molecular weight ladder (Invitrogen, Grand 
Island, NY, USA) was used for comparison of product size (Figure 2). 
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 Figure 2. Multiplex PCR for aminoglycoside modifying enzyme genes and mecA. The 
molecular size marker used in lanes 1 and 20 was the 1 Kb Plus DNA ladder (Invitrogen, 
Grand Island, NY). Template DNA used in the multiplex PCR was as follows: lanes 2 
and 15, S. aureus ATCC 29213; lanes 3 and 16, S. aureus ATCC 43300; lanes 4, 17, and 
19, no template DNA as a negative control; lanes 5 to 14, and 18, clinical S. 
pseudintermedius isolates (lane 5- isolate 13-089; lane 6-isolate 24-089, lane 7-isolate 
29-086, lane 8-isolate 30-027, lane 9-isolate 30-076, lane 10-isolate 30-077, lane 11-
isolate 31-094, lane 12-isolate 32-006, lane 13-isolate 32-010, lane 14-isolate 35-079; 
lane 18, isolate 30-077). Black arrows from top to bottom correspond to PCR products 
aac(6′)/aph(2′′) (predicted 491 bp), mecA (predicted 314 bp), aph(3′)- IIIa (predicted 
242 bp), and ant(4′)-Ia (predicted 135 bp), respectively. 
 
 
 
Statistical analysis 
Data were summarized using cross-tabulations and analyzed using chi-squared or 
Fisher’s exact tests, and logistic regression based on the binary outcome of amikacin 
resistance and binary outcomes of susceptibility for each of the other antimicrobials. 
Results of logistic regression were summarized as odds ratios (ORs) and 95% 
confidence intervals for the ORs, estimated using maximum likelihood methods. 
Analysis was performed at the level of isolate and ignored the fact that some isolates 
originated from the same dog. Significance was set at P < 0.05 and all analyses were 
performed using S-PLUS statistical software (Version 8.2; TIBCO, Inc., Seattle, WA). 
Results 
A total of 422 isolates were collected from 413 dogs. Of these 422 isolates, 369 (87%) 
were susceptible to amikacin and 53 (13%) were resistant to amikacin based on the CLSI 
interpretive criteria for amikacin (63). Of the 422 isolates, 338 (80%) were MSSP and 84 
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 (20%) were MRSP. All of the MRSP were positive for mecA by PCR.  There were 316 
isolates (75%) that were both MSSP and susceptible to amikacin, 53 (13%) that were 
MRSP but susceptible to amikacin, 22 (5%) that were MSSP but resistant to amikacin, 
and 31 (7%) that were MRSP and amikacin-resistant. The odds of an isolate being 
MRSP were significantly greater for isolates that were amikacin-resistant rather than 
amikacin-susceptible (Table 5). Resistance to each of the other antimicrobials tested was 
significantly associated with resistance to amikacin (Table 5). Because amikacin 
resistance was significantly associated with methicillin resistance, it was unclear whether 
resistance to the other antimicrobial drugs was associated with amikacin resistance alone 
or due to the association of amikacin resistance with methicillin resistance. Of the 422 S. 
pseudintermedius isolates, there were 106 isolates that were resistant to methicillin only 
(MR; n = 53), amikacin only (AR; n = 22), or both amikacin and methicillin (ARMR; n 
= 31). Among these 106 resistant S. pseudintermedius isolates, those that were resistant 
to both amikacin and methicillin were significantly more likely to be resistant to 
chloramphenicol, clindamycin, enrofloxacin, erythromycin, gentamicin, marbofloxacin, 
and trimethoprim/sulfonamide combination than the isolates that were either methicillin-
resistant or amikacin-resistant alone (Table 6). Of the antimicrobials examined, only 
resistance to doxycycline and rifampin were not more likely among S. pseudintermedius 
isolates resistant to both amikacin and methicillin relative to isolates that were only 
resistant to 1 drug (Table 6). Isolates with an MIC of ≥ 8 µg/ml were considered resistant 
to doxycycline.   
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 Table 5. Association of resistance to amikacin with resistance to other antimicrobials for 
isolates of Staphylococcus pseudintermedius (n = 422), expressed as odds ratios derived 
by logistic regression analysis. 
 
Antimicrobial 
agent(s) 
No. of amikacin-
susceptible 
isolates (%) 
No. of amikacin-
resistant isolates 
(%) 
Odds Ratio  
(95% CI) 
P-value 
Oxacillin     
   S 316 (93%) 22 (7%) 1 (NA)   
   R 53 (63%)  31 (37%) 8.4 (4.5 to 15.6) <0.0001 
Chloramphenicol     
   S 325 (92%) 30 (8%) 1 (NA)   
   R 44 (66%) 23 (34%) 5.7 (3.0 to 10.6) <0.0001 
Clindamycin     
   S 298 (96%) 11 (4%) 1 (NA)   
   R 71 (63%) 42 (37%) 16.0 (7.6 to 34.0) <0.0001 
Doxycycline     
   S 251 (95%) 13 (5%) 1 (NA)   
   R 117 (75%) 39 (25%) 6.4 (3.3 to 12.5) <0.0001 
Enrofloxacin     
   S 328 (95%) 18 (5%) 1 (NA)   
   R 41 (54%) 35 (46%) 15.6 (8.1 to 29.9) <0.0001 
Erythromycin     
   S 299 (96%) 11 (4%) 1 (NA)   
   R 68 (62%) 42 (38%) 16.8 (8.2 to 34.3) <0.0001 
Gentamicin     
   S 348 (100%) 0 (0%)  1 (NA)   
   R 21 (28%) 53 (72%) Inestimable* <0.0001* 
Marbofloxacin     
   S 331 (92%) 27 (8%) 1 (NA)   
   R 37 (59%) 26 (41%) 8.6 (4.6 to 16.3) <0.0001 
Rifampin     
   S 359 (88%) 48 (12%) 1 (NA)   
   R   8 (62%) 5 (38%) 4.7 (1.5 to 14.9) 0.0093 
Trimethoprim/Sulfa     
   S 309 (96%) 14 (4%) 1 (NA)   
   R 58 (60%) 39 (40%) 14.8 (7.6 to 28.9) <0.0001 
S = Susceptible, R = Resistant 
*Inestimable because of complete separation (i.e., no isolate resistant to amikacin was 
susceptible to gentamicin); P value derived from chi-square test with continuity 
correction 
NA = Not applicable (reference category) 
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 Table 6.  Association of resistance to amikacin and/or methicillin relative to resistance 
to other antimicrobials in Staphylococcus pseudintermedius isolates (n = 106) 
 
Antimicrobial 
agent(s) 
No. of AR & 
MR (%) 
No. of AR or 
MR (%) 
Odds Ratio  
(95% CI) 
P-value 
Chloramphenicol     
   S 14 (22  50 (78%) 1 (NA)   
   R 17 (40%) 25 (60%) 4.9 (1.2 to 4.9) 0.0444 
Clindamycin     
   S 1 (5%) 21 (95%) 1 (NA)   
   R 30 (36%) 54 (64%) 11.6 (1.5 to 85.7) 0.0177 
Doxycycline     
   S 5 (22%) 18 (78%) 1 (NA)   
   R 25 (31%) 56 (69%) 1.6 (0.5 to 4.8)  0.3986 
Enrofloxacin     
   S 2 (5%) 35 (95%) 1 (NA)   
   R 29 (42%) 40 (58%) 12.7 (2.8 to 56.9) 0.0012 
Erythromycin     
   S 1 (4%) 22 (96%) 1 (NA)   
   R 30 (37%) 51 (63%) 12.9 (1.8 to 95.0) 0.0135 
Gentamicin     
   S 0 (0%) 38 (100%) 1 (NA)   
   R 31 (46%) 37 (54%) Inestimable* <0.0001* 
Marbofloxacin     
   S 8 (17%) 40 (83%) 1 (NA)   
   R 23 (40%) 34 (60%) 3.4 (1.3 to 8.5)  0.0112 
Rifampin     
   S 1 (29%) 65 (71%) 1 (NA)   
   R 4 (31%) 5 (69%) 1.1 (0.3 to 3.8) 0.9163 
Trimethoprim/Sulfa     
   S 0 (0%)  26 (100%) 1 (NA)   
   R 31 (40%) 47 (60%) Inestimable* 0.0003* 
S = susceptible, R = resistant, AR & MR = isolates resistant to amikacin and oxacillin, 
AR or MR = isolates resistant to amikacin or oxacillin  
*Inestimable because of complete separation (No observations in one category); P value 
derived from chi-square test with continuity correction 
NA = Not applicable (reference category) 
 
 
 
There were 32 isolates from 32 unique dogs available for identification of 
amikacin resistance genes. A retrospective analysis of patient records associated with the 
isolates was performed. Among these 32 dogs the majority were treated on an outpatient 
basis (59%; 19/32) while the remainder (41%; 13/32) were hospitalized. Of the 13 
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 isolates from hospitalized patients, 4 were MSSP.  Of the 9 MRSP isolates, 4 were 
susceptible to marbofloxacin, clindamycin or chloramphenicol while 5 were resistant to 
all other drugs except rifampin.  The median time of culture upon entry into the hospital 
was zero days (SD = 2.2 days; range 0 to 12 days) with day zero defined as entry into the 
hospital for either the patient appointment or clinical emergency. Most samples (69%; 
22/32) were collected on day zero. Cultures were primarily taken from sources of skin 
disease (72%; 23/32). The majority of these samples were collected from patients with 
pyoderma skin lesions (47%; 15/32) followed by skin wounds (12%; 4/32). The next 
most common sites sampled were urine and orthopedic implants, both seen in 3/32 
cultures (9%).  
Of the 32 dogs, 81% (26/32) had a history of prior antimicrobial administration, 
of which 53% (17/26) had received antimicrobials within 6 weeks. Of the 26 dogs with a 
history of antimicrobial administration, 54% (14/26) had received monotherapy while 
46% (12/26) had received multiple antimicrobials before their culture was taken. Only 
19% (6/32) reported no history of prior antimicrobial use. There was no significant 
difference (P = 1.0000; Fisher’s exact test) in whether dogs with amikacin-resistant 
isolates had a history of prior antimicrobial administration and whether their isolates 
were MSSP (82%; 9/11) or MRSP (81%; 17/21). The distribution of the three categories 
of prior antimicrobials (none, monotherapy, multi-drug) did not differ significantly (P = 
0.7926; Fisher’s exact test) between amikacin-resistant isolates that were MSSP and 
MRSP. Similarly, the proportion of dogs that received multiple drugs did not differ 
significantly (P = 0.6530) between isolates that were MSSP (27%; 3/11) and those that 
were MRSP (43%; 9/21). However, using logistic regression analysis, the odds of an 
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 MRSP isolate coming from a dog with a history of antimicrobials within the preceding 6 
weeks of culture was significantly (P = 0.0498) greater than for MSSP isolates (OR = 
5.3; 95% CI = 1.1 to 26.6).   
Among amikacin-resistant isolates, 66% (21/32) were concurrently methicillin-
resistant while 34% (11/32) were methicillin-susceptible. Of the 32 amikacin-resistant 
isolates tested, the gene aac(6′)/aph(2′′) was present in 12% (4/32) isolates, the gene 
aph(3′)- IIIa was present in 75% (24/32) isolates, and the gene ant(4′)-Ia was present in 
3% (1/32) isolates. There were four amikacin-resistant isolates in which none of these 
three genes were detected. Some isolates carried more than one gene. Representative 
PCR results are shown in Figure 2. There was no association between methicillin 
resistance and carriage of a specific amikacin resistance gene. The aph(3′)- IIIa gene 
tended to be more prevalent among isolates that were MRSP (86%; 18/21) compared to 
MSSP isolates (55%; 6/11); however, this difference was not significant (P = 0.0877; 
Fisher's exact test). The proportion of MRSP isolates that carried the aac(6′)/aph(2′′) 
gene (5%; 1/21) was less than that of MSSP isolates (27%; 3/11); however, this 
difference was not significant (P = 0.1055; Fisher's exact test). The 1 isolate that carried 
the ant(4′)-Ia gene was MRSP.   
Discussion 
Staphylococcus pseudintermedius is the most common bacterial pathogen associated 
with canine pyoderma and post-operative wound infections (1,2). Treatment of these 
infections typically involves β-lactam antibiotics such as amoxicillin and cephalexin. 
The spread of methicillin-resistant S. pseudintermedius (MRSP) across Europe led to the 
widespread use of alternative antibiotics such as chloramphenicol (2,10). This ultimately 
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 led to resistance to chloramphenicol and virtually all classes of antibiotics approved for 
use in dogs (2,10). Methicillin resistance has begun to emerge in the United States and 
over the past 5 years, resistance to chloramphenicol has become common (Table 4). This 
has led to reliance on other antimicrobial drugs such as amikacin to treat life-threatening 
MRSP infections. During the past two years, aminoglycoside-resistant MRSP have been 
identified among patients in our small animal hospital (Table 4). Aminoglycosides like 
amikacin are not routinely used to treat staphylococcal infections due to potential 
nephrotoxic effects of these drugs and inconvenient route of administration (12,55). The 
increased prevalence of methicillin-resistant and multi-drug resistant S. 
pseudintermedius has left clinicians with few choices for antimicrobial therapy 
sometimes making aminoglycosides a last available choice for therapy. 
Aminoglycosides are bactericidal agents that bind irreversibly to the 30S 
ribosomal subunit of susceptible bacteria thereby inhibiting protein synthesis (13). Drug 
inactivation by AMEs is the main mechanism of aminoglycoside resistance (14,17,19). 
In a study of S. aureus, the aac(6′)/aph(2′′) gene was found in 66% of resistant S. aureus 
isolates followed by ant(4′)-Ia and aph(3′)- IIIa genes with frequencies of 24% and 8%, 
respectively (14). Similar results have previously been found (18). In contrast, we found 
that in S. pseudintermedius, the most common amikacin resistance gene was aph(3′)- 
IIIa, which was present in 75% (24/32) of amikacin-resistant isolates of S. 
pseudintermedius followed by aac(6′)/aph(2′′) and ant(4′)-Ia genes with 12% (4/32) and 
3% (1/32), respectively. The gene aph(3′)- IIIa has been demonstrated in the 
chromosomal DNA of S. pseudintermedius strains as well as on transposons carried on 
plasmids (7,123,124). It is unclear whether aph(3′)- IIIa is carried on the chromosome or 
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 on a plasmid and whether or not it is part of a transposable element in the strains in our 
study. Understanding which resistance genes are present and how they are transmitted 
has important clinical ramifications for infected patients. Under antimicrobial selective 
pressure, antibiotic resistance genes can be transferred from one strain or species of 
Staphylococcus to another by plasmid conjugation, phage-mediated transduction, or 
transposon movement and could result in the widespread of antibiotic resistance among 
staphylococci (7).  
Our study is limited by its retrospective nature. Patient histories were obtained 
solely through the available medical records. Some cases may have had previous 
cultures or antimicrobial therapy that was not noted in the records. Due to the use of an 
antimicrobial susceptibility testing system that did not measure amikacin MICs, 
amikacin-resistant isolates may have been missed prior to 2010. Additionally, the 
exclusion of 21 amikacin-resistant isolates from genetic testing because they were not 
stored at the time of isolation may have affected the prevalence of certain amikacin-
resistance genes. Despite these limitations, we documented a 15% rise in 
aminoglycoside resistance at the VMTH over the past 2 years (Table 4) and determined 
that aph(3′)- IIIa was the most common gene in isolates from patients presented to our 
hospital. Another limitation of our study is that without genetic fingerprinting, spa 
typing or other method to compare the genetic relatedness of the isolates, we cannot rule 
out the possibility that some of the isolates represent a nosocomial clone, particularly for 
the 5 MRSP isolates from inpatients that were resistant to all other drugs.  Finally, this 
study found that doxycycline resistance was not more likely in isolates that were both 
amikacin-resistant and methicillin-resistant as compared to isolates that were either 
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 amikacin or methicillin resistant.  In 2013 a strong case was made for the adoption of 
canine breakpoints for doxycycline (susceptible, ≤0.125 µg/ml; intermediate, 0.25 
µg/ml; resistant, >0.5 µg/ml) for S. pseudintermedius isolates instead of using the human 
breakpoints (susceptible, ≤4 µg/ml; intermediate, 8 µg/ml; resistant, >16 µg/ml).  The 
majority of isolates from this study (250/422) had an MIC ≤2 µg/ml.  It is possible that if 
we had used the more conservative breakpoints we would have found that doxycycline 
resistance was more likely in isolates that were both methicillin- and amikacin-resistant. 
Unfortunately we were unable to test this as the lowest concentration of doxycycline 
available on the commercial microbroth dilution system used by our laboratory is 2 
µg/ml, well above the proposed breakpoint for canine staphylococcal isolates and not all 
of the isolates tested by the laboratory were available for re-testing.  
This study also found a significant association between amikacin resistance and 
methicillin resistance (Table 5). Similarly, a study in S. aureus and coagulase negative 
staphylococci identified the presence of at least one AME gene associated with mecA in 
72% of the methicillin-resistant staphylococci (14). One theory, aside from gene transfer 
from another source, as to why these genes seem to be commonly present together is that 
mecA and the AME genes may be located adjacent to each other on the bacterial 
chromosome (125,126). Among the isolates in this study, resistance to other drugs was 
more likely to be found in isolates that were both amikacin- and methicillin-resistant 
(Table 6). This may reflect development of amikacin resistance as a result of treatment 
of multi-drug resistant MRSP with amikacin but does not explain the finding of 
amikacin-resistant isolates that were susceptible to all other drugs. Within the 422 S. 
pseudintermedius isolates, there were 22 isolates that were amikacin-resistant but 
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 methicillin-susceptible. In these isolates, it is possible, although unproven, that amikacin 
resistance may be plasmid-mediated.  If this is true, the association between amikacin 
and methicillin resistance may change over time and future studies may find that 
amikacin resistance is not linked with methicillin resistance.  
Aminoglycosides remain important antimicrobial drugs for the treatment of life-
threatening infections in veterinary medicine even though resistance among species of 
staphylococci continues to be demonstrated worldwide (14,127). Since AMEs can be 
carried on plasmids or on transposable elements, it may be important to monitor 
aminoglycoside resistance in staphylococci over time as transmission of resistance 
between bacterial strains or species (for example from S. pseudintermedius to S. aureus) 
may represent a new nosocomial and zoonotic threat, particularly in the face of increased 
multi-drug resistant staphylococci (7,17,128). 
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 CHAPTER V 
INDUCIBLE CLINDAMYCIN RESISTANCE∗ 
 
Introduction 
Increased prevalence of methicillin resistance and multi-drug resistance in 
Staphylococcus pseudintermedius has resulted in greater use of clindamycin to treat 
canine pyoderma because of its perceived clinical efficacy and good distribution to the 
skin (9,12). Clindamycin is a lincosamide that reversibly binds to the bacterial 50S 
ribosomal subunit thereby inhibiting protein synthesis (20). In some cases, staphylococci 
may appear to be susceptible to clindamycin when tested in vitro, but the infected patient 
may fail to respond to therapy despite being treated with what seems to be an appropriate 
drug concentration for an appropriate duration. Lincosamides bind to the same or closely 
related binding sites in the bacterial ribosome as macrolides such as erythromycin. 
Resistance to macrolides, lincosamides, and streptogramin B antibiotics (MLSB 
phenotype) can occur through acquisition of a methylase enzyme that removes a methyl 
group from an adenine residue in the 23S ribosomal RNA component of the 50S subunit 
of the ribosome (21-23). Removal of this methyl group alters the site to which the 
antimicrobial drug binds altering its efficacy. An active efflux pump encoded by the 
msrA gene also confers resistance to macrolides and streptogramin antibiotics but not 
lincosamides such as clindamycin (MS phenotype) (23). 
∗Reprinted with permission from “Incidence of inducible clindamycin resistance in 
Staphylococcus pseudintermedius from dogs” by Gold RM, Cohen ND, Lawhon SD, 
2013. Journal of Clinical Microbiology, 51, 4196-4199, Copyright [2014] by American 
Society for Microbiology. 
62 
 
                                                 
 Approximately forty erm genes that encode methylases have been reported in 
different bacterial genera, with ermA, ermB, and ermC the most commonly found among 
staphylococci (24). In S. aureus, ermA and ermC confer erythromycin resistance in 94-
98% of isolates (25). In S. pseudintermedius, ermB is primarily responsible for MLSB 
resistance, but its expression can be constitutive or inducible (11). Mutation in the 
macrolide-inducible DNA sequence preceding ermB genes can alter resistance from 
inducible to constitutive (129). These mutations occur at a rate of about one in every 
2×106 replications (130,131). Infections in which bacteria are present and dividing in 
purulent material in numbers greater than this are common, which means that these 
mutations readily occur, resulting in constitutive MLS resistance, and strains carrying 
the mutation will dominate within the bacterial population at the site of infection, 
particularly in the presence of antimicrobial selection pressure (129). Therefore, if 
bacteria carrying inducible MLSB resistance are present in an infection, such mutations 
may result in constitutive MLSB resistance leading to treatment failure. Routine 
antimicrobial susceptibility testing can detect constitutive MLSB resistance but fails to 
detect inducible resistance (26). Detailed descriptions of the mechanisms of erm gene 
expression and mutations leading to constitutive MLSB resistance have been previously 
published (129,130).  Inducible clindamycin resistance can result in treatment failure and 
should be suspected in isolates that are erythromycin-resistant but clindamycin-
susceptible on in vitro antimicrobial susceptibility testing. In this study we evaluated the 
frequency of inducible clindamycin resistance in S. pseudintermedius from patients 
presented to the Texas A&M Veterinary Medical Teaching Hospital (VMTH) by double 
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 disk diffusion testing (“D-test”) for inducible clindamycin resistance and the presence of 
ermB by polymerase chain reaction (PCR).   
Materials and methods 
A total of 608 canine Staphylococcus pseudintermedius isolates collected from the 
VMTH between 2007-2012 were screened for inducible clindamycin resistance. At the 
time of initial collection, all isolates were presumptively identified as S. 
pseudintermedius based on Gram stain, colony color, polymyxin B susceptibility, 
production of coagulase and catalase, and ability to grow on salt-mannitol agar. All 
isolates were tested for antimicrobial susceptibility using commercially available 
systems (VITEK, bioMérieux, Durham, NC or TREK Sensititre, TREK Diagnostics, 
Cleveland, OH) according to the Clinical and Laboratory Standards Institute (CLSI) 
guidelines for MIC testing (132). Isolates were screened to identify those that were 
intermediate or resistant to erythromycin and susceptible or intermediate to clindamycin. 
Those meeting the criteria were further tested for the presence of a positive D-test 
according to the CLSI guidelines (112). Quality control strains for antimicrobial 
susceptibility testing included S. aureus ATCC 43300, ATCC 25923, and ATCC 29213. 
Quality control strains for the D-test included S. aureus BAA-977 and BAA-976. All 
quality control strains were obtained from the American Type Culture Collection 
(ATCC) (Manassas, VA). Eight isolates met the screening criteria and underwent further 
testing. All eight were susceptible for clindamycin on the MIC panel; seven were 
erythromycin-resistant and one was intermediate to erythromycin. One isolate exhibited 
intermediate resistance to clindamycin; however, it was susceptible to erythromycin and 
was not tested further. Species identification of the eight isolates was confirmed by PCR 
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 using primers and methods previously described (133). Bacterial DNA was purified for 
the ermB PCR using a DNeasy Blood & Tissue Kit (Qiagen, Germantown, MD) 
according to the manufacturer’s instructions for gram-positive bacteria. PCR 
amplification of a 639 base pair product specific for ermB was performed using primers 
(5) and methods (134) previously described  with an alteration in the annealing 
temperature to 460C followed by 1% gel electrophoresis. All primers and PCR reagents 
were purchased from Sigma-Genosys, Houston, TX and Takara Bio Company, Otsu, 
Shiga, Japan respectively. The resultant PCR product was confirmed as ermB by 
sequencing at the DNA Core Laboratory at the Texas A&M University College of 
Veterinary Medicine. 
Results and discussion  
The isolates in this study came from eight dogs that presented to the VMTH between 
February 2008 and April 2010. Two isolates were isolated from each of the following 
sites: infected tibial plateau leveling osteotomy (TPLO) implants, skin lesions, and the 
urinary tract (one from an infection and one from a bladder stone). One of the skin lesion 
isolates came from a dog with generalized demodicosis and deep pyoderma, and the 
second was collected from the pre-scrubbed surgical site for a torn cranial cruciate 
ligament repair. The remaining two isolates came from a blood culture and post-surgical 
lavage of the peritoneum following exploratory abdominal surgery.  
Upon presentation to the VMTH, six of the eight dogs had received prior 
antibiotic therapy with one or more antimicrobial drugs within six weeks of entering the 
hospital. Five of these dogs were receiving antimicrobial therapy at the time of culture.  
One dog received erythromycin and another received clindamycin. In this study, all 
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isolates considered resistant or intermediate to erythromycin but susceptible to 
clindamycin in vitro tested positive for inducible clindamycin resistance by D-test and 
the presence of ermB associated with MLSB resistance (Table 7, Figure 3). Two of the 
isolates were methicillin-susceptible (25%) while the remaining six were methicillin-
resistant (75%).  
Table 7. Inducible clindamycin resistance, erythromycin resistance, and oxacillin 
resistance in Staphylococcus pseudintermedius. 
Isolate No. MIC (µg/mL) with Interpretation
a D-test 
Result 
PCR test for 
ermB Clindamycin Erythromycin Oxacillin 
11-001 ≤0.5 (S) ≥8 (R) ≥8 (R) Positive Positive 
11-025 ≤0.5 (S) ≥8 (R) ≥8 (R) Positive Positive 
11-033 ≤0.5 (S) 1 (I) ≥8 (R) Positive Positive 
11-064 ≤0.5 (S) ≥8 (R) ≥8 (R) Positive Positive 
12-012 ≤0.5 (S) ≥8 (R) ≤0.25 (S) Positive Positive 
17-016 ≤0.5 (S) ≥8 (R) 2 (R) Positive Positive 
18-007 ≤0.5 (S) ≥8 (R) ≥8 (R) Positive Positive 
24-014 ≤0.5 (S) ≥8 (R) ≤0.25 (S) Positive Positive 
aMinimum Inhibitory Concentration (MIC) for clindamycin, erythromycin, and 
oxacillin. Breakpoints for antimicrobials were from CLSI VET01-A4 (112). 
Abbreviations for interpretations were as follows: R = Resistant to antimicrobial; S = 
Susceptible to antimicrobial; I = Intermediate susceptibility to antimicrobial.  Guidelines 
for D-test performance and interpretation were from CLSI M02-A11 (112). 
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Figure 3. Disk diffusion testing for inducible clindamycin resistance of Staphylococcus 
pseudintermedius isolates. The disk labeled E15 contained15 µg of erythromycin and the 
disk labeled CC2 contained 2 µg of clindamycin. The disks are spaced 15mm apart; (A) 
ATCC 25923 Staphylococcus aureus, erythromycin- and clindamycin-susceptible, 
negative D-test. (B) S. pseudintermedius clinical isolate 11-012, erythromycin- and 
clindamycin-resistant, negative D-test; (C) BAA-976 S. aureus, erythromycin-resistant, 
clindamycin-susceptible, negative D-test; (D) BAA-977 S. aureus, erythromycin-
resistant, inducible clindamycin-resistant, positive D-test. 
 
 
 
 S. pseudintermedius is the most common bacterial agent isolated from canine 
pyoderma and surgical and non-surgical wound infections (1,2). Of the eight dogs that 
provided isolates evaluated in this study, four had skin lesions or TPLO implant-related 
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 surgical infections. Treatment of staphylococcal infection at these sites in dogs typically 
involves therapy with β-lactam antibiotics such as penicillins and cephalosporins. With 
increased prevalence of methicillin resistance, alternatives to β-lactam antibiotics have 
been sought (12,55). In addition to being resistant to β-lactam antibiotics, methicillin-
resistant S. pseudintermedius (MRSP) strains are increasingly resistant to other 
antibiotics. A recent multi-center study in Europe and North America showed that 
MRSP isolates are commonly resistant to virtually all classes of antibiotics approved for 
use in dogs (2,10).  Six of the isolates in this study were MRSP strains while two were 
methicillin-susceptible. In methicillin-resistant Staphylococcus from North America 
collected from 2006-2008, 17.7% (11/62) of S. aureus isolates carried inducible 
clindamycin resistance vs. 0% (0/46) of S. pseudintermedius isolates (81). In MRSP 
isolates from Europe and North America collected from 2004-2009 1.9% (2/103) of 
isolates were positive for ermB and displayed inducible resistance to clindamycin (11). 
In the study described here, the differences in inducible clindamycin resistance could be 
attributed to either rapid changes in antimicrobial resistance patterns or geographic 
differences in the occurrence of inducible resistance. 
Increased methicillin resistance and inducible clindamycin resistance in S. 
pseudintermedius has significant implications for canine and human health. While S. 
pseudintermedius infection in humans is relatively uncommon, zoonotic transmission of 
S. pseudintermedius to the owner of an infected pet or veterinary staff is a potential 
threat (1,4). Recent studies have demonstrated that 5.3% of veterinary dermatologists 
and their technical staff carry MRSP and that owners of dogs with deep pyoderma can 
carry identical S. pseudintermedius strains to those carried by their infected pets (1,101). 
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 Additionally, there is the potential for transmission of antimicrobial resistance genes 
from canine isolates of S. pseudintermedius to human isolates of S. aureus (135,136). 
For empiric, systemic treatment of canine pyoderma, amoxicillin/clavulanate and 
first-generation cephalosporins are the most common first-line drugs selected (9). With 
increased occurrence of antimicrobial resistance, clindamycin is recommended as an 
appropriate, alternative choice due to its favorable safety profile, clinical efficacy, and 
distribution into the skin (9,12). Infections refractory to empiric therapy should be 
cultured and isolated bacteria tested for antimicrobial susceptibility. S. pseudintermedius 
isolates that are resistant to macrolides such as erythromycin but susceptible to 
clindamycin should be tested for the presence of inducible clindamycin resistance either 
by D-test or genetic testing. While the occurrence of such isolates is relatively low 
(1.32%; 8/608 in our study), failure to detect these isolates can result in treatment 
failures in infected patients and associated increased patient morbidity and expense for 
clients. In two of the cases presented here, clindamycin was used for antibiotic therapy 
resulting in treatment failure. Clinicians must recognize the potential for inducible 
clindamycin resistance and be able to recognize the potentially predictive pattern on 
antimicrobial susceptibility results. Performing the D-test is not a standard practice in all 
microbiology laboratories. The laboratory should be asked to perform this test whenever 
a S. pseudintermedius isolate is reported as susceptible (or intermediate) to clindamycin 
while resistant (or intermediate) to erythromycin on in vitro antimicrobial susceptibility 
tests (80). 
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CONCLUSIONS 
 
S. pseudintermedius is the most frequent causative agent of canine pyoderma and is also 
associated with opportunistic infections in dogs (otitis externa, urinary tract infections, 
and surgical and non-surgical wound infections) (1,2). Many dogs harbor S. 
pseudintermedius in their nares and elsewhere on their skin without having clinical 
evidence of disease and for this reason serve as a potential source of infection for other 
animals and humans as well (1,3,4). When empirical treatment fails or infection 
reoccurs, culture and antimicrobial susceptibility testing of a sample should be 
performed to guide selection of an appropriate alternate antimicrobial drug. 
In this study, MRSP was strongly associated with clinical disease. While there 
was no significant difference between sps gene and source in this study it is interesting 
that the majority of isolates with multiple genes were from dogs that had pyoderma. In 
addition, spsP and spsQ were significantly associated with methicillin resistance. This 
new information may impact the development of S. pseudintermedius vaccines or 
alternative therapies for staphylococcal infections in dogs as antibiotic resistance rates 
are on the rise.  
In recent years isolation of methicillin-resistant S. pseudintermedius (MRSP) 
from canine skin has become common and veterinarians have attempted to utilize other 
classes of antimicrobial drugs. Unfortunately, studies from Europe have demonstrated 
that 90% of MRSP isolates were resistant to clindamycin, erythromycin, and 
trimethoprim, 70% were resistant to both chloramphenicol and gentamicin, and 57% 
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 were resistant to just chloramphenicol (2,10). Resistance has begun to emerge in the 
United States: over the past five years, resistance to chloramphenicol has become 
common leading to the reliance on drugs such as amikacin to treat MRSP infection 
(11,12). Aminoglycosides remain important antimicrobial drugs for the treatment of life-
threatening infections in veterinary medicine, however, this study found a significant 
association between amikacin resistance and methicillin resistance. Since AMEs can be 
carried on plasmids or on transposable elements, it may be important to monitor 
aminoglycoside resistance in staphylococci over time as transmission of resistance 
between bacterial strains or species (for example from S. pseudintermedius to S. aureus) 
may represent a new nosocomial and zoonotic threat, particularly in the face of increased 
multi-drug resistant staphylococci (7,17,128). 
Finally, the rise in MRSP cases raises a number of questions about the diagnosis, 
treatment, and prevention of these infections. As such it is imprudent to compound the 
problem by adding to patient morbidity simply due to diagnostic error. S. 
pseudintermedius isolates that are resistant to macrolides such as erythromycin but 
susceptible to clindamycin should be tested for the presence of inducible clindamycin 
resistance either by D-test or genetic testing. While the occurrence of such isolates is 
relatively low (1.32%; 8/608 in our study), failure to detect these isolates can result in 
treatment failures in infected patients and associated increased patient morbidity and 
expense for clients. In two of the cases presented in this study, clindamycin was used for 
antibiotic therapy resulting in treatment failure. Clinicians must recognize the potential 
for inducible clindamycin resistance and be able to recognize the potentially predictive 
pattern on antimicrobial susceptibility results. Performing the D-test is not a standard 
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 practice in all microbiology laboratories. The laboratory should be asked to perform this 
test whenever a S. pseudintermedius isolate is reported as susceptible (or intermediate) to 
clindamycin while resistant (or intermediate) to erythromycin on in vitro antimicrobial 
susceptibility tests (80). 
Because they are uniquely adapted commensal organisms, staphylococci are 
likely to remain a cause of opportunistic infection in humans and animals. 
Staphylococcal infections can range from simple skin infections and dermatologic 
disorders to severe systemic bacteremias that can cause multiorgan failure and death 
(33,42,51). Debate remains about whether there are differences between MRSA and 
MRSP infections in dogs with regard to severity of clinical signs and outcome. 
Additional research is needed to improve our understanding of S. pseudintermedius 
infection in dogs as resistance rates continue to rise rendering are current medications 
ineffective. 
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